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reamble
he American College of Cardiology Foundation (ACCF)
d the American Heart Association (AHA) support their
embers’ goal to improve the prevention and care of
rdiovascular diseases through professional education,
search, and development of guidelines and standards and
fostering policy that supports optimal patient outcomes.
he ACCF and AHA recognize the importance of the use
clinical data standards for patient management, to assess
tcomes, and conduct research and the importance of
fining the processes and outcomes of clinical care, cohether in randomized trials, observational studies, regis-
ies, or quality improvement initiatives.
Hence, clinical data standards strive to define and standard-
e data relevant to clinical topics in cardiology, with the
imary goal of assisting data collection by providing a
atform of data elements and definitions applicable to
rious conditions. Broad agreement on a common vocabu-
ry with reliable definitions used by all is vital to pool and/or
mpare data across studies to promote interoperability of
ectronic health records and to assess the applicability of
search to clinical practice. The increasing national focus on
option of certified electronic health records along with
nancial incentives for providers to demonstrate “meaningful
e” of those electronic health records to improve healthcare
ality render even more imperative and urgent the need for
ch definitions and standards. Therefore, the ACCF and
HA have undertaken to define and disseminate clinical data
andards: sets of standardized data elements and correspond-
g definitions to collect data relevant to cardiovascular
nditions. The ultimate purpose of clinical data standards is
contribute to the infrastructure necessary to accomplish the
CCF/AHA’s missions of fostering optimal cardiovascular
re and disease prevention and building healthier lives, free
cardiovascular diseases and stroke, respectively.
The specific goals of clinical data standards are
To establish a consistent, interoperable, and universal
clinical vocabulary as a foundation to both clinical care
and clinical research
To promote the ubiquitous use of electronic health records
and facilitate the exchange of data across systems through
harmonized, standardized definitions of key data elements
To facilitate the further development of clinical registries,
quality and performance improvement programs, out-
comes evaluations, and clinical research, including the
comparison of results within and across these initiatives
he key elements and definitions are a compilation of
riables intended to facilitate the consistent, accurate, and
producible capture of clinical concepts; standardize the
rminology used to describe cardiovascular diseases and
ocedures; create a data environment conducive to the
sessment of patient management and outcomes for quality
d performance improvement and for clinical and transla-
onal research; and increase opportunities for sharing data
ross disparate data sources. The ACCF/AHA Task Force on
linical Data Standards selects cardiovascular conditions and
ocedures that will benefit from creating a data standard set.
xperts in the subject are selected to examine/consider
isting standards and develop a comprehensive, yet not
haustive, data standard set. When undertaking a data
llection effort, only a subset of the elements contained in a
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ACCF/AHA PAVD Data Standards January 17, 2012:294–357inical data standards listing may be needed, or, conversely,
ers may want to consider whether it may be necessary to
llect some elements not listed. For example, in the setting
a randomized clinical trial of a new drug, additional
formation regarding study procedures and drug therapies
ould likely be required.
The ACCF and AHA recognize that there are other
tional efforts to establish clinical data standards, and every
tempt is made to harmonize newly published standards with
isting standards. Writing committees are instructed to
nsider adopting or adapting existing nationally recognized
ta standards if the definitions and characteristics are useful
d applicable to the set under development. In addition, the
CCF and AHA are committed to continually expanding
eir portfolio of data standards and will create new standards
d update existing standards as needed to maintain their
rrency and promote harmonization with other standards as
alth information technology and clinical practice evolve.
The Health Insurance Portability and Accountability Act
IPAA) privacy regulations, which went into effect in April
03, have heightened all practitioners’ awareness of our
ofessional commitment to safeguard patients’ privacy. The
IPAA privacy regulations (1) specify which information
ements are considered “protected health information.”
hese elements may not be disclosed to third parties (includ-
g registries and research studies) without the patient’s
ritten permission. Protected health information may be
cluded in databases used for healthcare operations under a
ta use agreement. Research studies using protected health
formation must be reviewed by an institutional review
ard or a privacy board.
We have included identifying information in all clinical
ta standards to facilitate uniform collection of these ele-
ents when appropriate. For example, a longitudinal clinic
tabase may contain these elements, because access is
stricted to the patient’s caregivers. On the other hand,
gistries may not contain protected health information unless
ecific permission is granted by each patient. These fields
e indicated as protected health information in the data
andards.
The ACCF/AHA Task Force on Clinical Data Standards
akes every effort to avoid any actual or potential conflicts of
terest that may arise as a result of an outside relationship or
personal, professional, or business interest of a member of
e writing panel. Specifically, all members of the writing
oup were required to submit a disclosure form showing all
ch relationships that might be perceived as real or potential
nflicts of interest. These statements are reviewed by the
CCF/AHA Task Force on Clinical Data Standards, reported
ally to all members of the writing panel at the first meeting,
d updated as changes occur. Writing committee members’
lationships with industry or other entities (RWI) are listed
Appendix 1. Official peer reviewers’ RWI are listed in
ppendix 2.
In clinical care, caregivers communicate with each other
rough a common vocabulary. In an analogous fashion, the
tegrity of clinical research depends on firm adherence to
especified procedures for patient enrollment and follow-up; ouese procedures are guaranteed through careful attention to
finitions enumerated in the study design and case report
rms. When data elements and definitions are standardized
ross studies, comparisons, pooled analysis, and meta-
alysis are enabled, thus deepening our understanding of
dividual studies.
The recent development of quality performance measure-
ent initiatives, particularly those for which comparison of
oviders is an implicit or explicit aim, has further raised
areness about the importance of data standards. Indeed, a
ide audience, including nonmedical professionals such as
yers, regulators, and consumers, may draw conclusions
out care and outcomes. To understand and compare care
tterns and outcomes, the data elements that characterize
em must be clearly defined, consistently used, and properly
terpreted, now more than ever before.
Robert C. Hendel, MD, FACC, FASNC, FAHA
hair, ACCF/AHA Task Force on Clinical Data Standards
. Introduction
therosclerotic vascular disease refers to disorders of the
teries caused by atherosclerosis (2). This document pro-
des data standards for peripheral atherosclerotic vascular
seases (PAVDs), including lower extremity peripheral ar-
ry disease (PAD), abdominal aortic aneurysm (AAA), renal
d mesenteric artery disease, and extracranial carotid artery
sease. It may serve as a companion to the “2005 ACC/AHA
uidelines for the Management of Patients With Peripheral
rterial Disease” (3), the “2011 ACCF/AHA Focused Update
the Guideline for the Management of Patients With
eripheral Artery Disease” (4), and the “2010 ACCF/AHA
erformance Measures for Adults With Peripheral Artery
isease” (5). Coronary artery disease is outside the scope of
is document. Multiple disciplines are engaged in the eval-
tion and management of patients with PAVDs, and devel-
ments in relevant research and technology are emerging
pidly. Therefore, to ensure optimal documentation and
mmunication among healthcare providers, researchers, pol-
y makers, payers, and industry, the establishment of a
iform set of data elements and definitions for PAVDs could
t be more timely and compelling.
The data standards covered in this document are divided
to 6 distinct tables. The first table covers general data
ements common to all PAVDs, including demographic
formation, atherosclerotic risk factors, concurrent athero-
lerotic diseases, comorbid conditions, medications, the
rdiovascular examination, and relevant blood chemistries
d hematology. The remaining tables cover data standards
ecific for lower extremity PAD, AAA, renal artery disease,
esenteric artery disease, and extracranial carotid and verte-
al artery disease, respectively. Each of the disease-specific
bles includes the following data elements: medical history,
ysical examination, laboratory testing, diagnostic proce-
res, invasive therapeutic procedures (both endovascular
d open surgical), pharmacological therapy, follow-up, and
tcomes.
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.1. Writing Committee Composition
he ACCF/AHA Task Force on Clinical Data Standards
lected members for the Writing Committee to Develop
linical Data Standards for Peripheral Atherosclerotic Vas-
lar Disease. The writing committee consisted of 23 mem-
rs who are well versed in the epidemiology, clinical
aluation, medical management, invasive therapy, and/or
tcomes assessment of patients with vascular disease and
cluded members with expertise in patient care, clinical
vestigation, and healthcare services research and delivery.
he writing committee included representatives from a broad
nge of cardiovascular professional societies and organiza-
ons to ensure that the content of this document is widely
plicable. All partnering and collaborating organizations
minated people to serve on the writing committee.
.2. Relationships With Industry and
ther Entities
he ACCF/AHA Task Force on Clinical Data Standards
akes every effort to avoid any actual, potential, or
rceived conflicts of interest that may arise as a result of
WI among members of the writing committee. Specifi-
lly, all members of the writing group, as well as peer
viewers of the document, were required to disclose all
rrent relationships and those that existed 24 months
fore initiation of this writing effort that might be
rceived as relevant. These statements were reviewed by
e ACCF/AHA Task Force on Clinical Data Standards
d by all members during each conference call or meeting
the writing committee and updated when changes
curred. This writing effort was initiated before the
plementation of the updated ACCF and AHA policy on
WI, which requires that the writing committee chair plus
majority of the writing committee have no relevant RWI.
elevant RWI disclosed by writing committee members
d peer reviewers are listed in Appendixes 1 and 2,
spectively. Comprehensive disclosure information for
e Task Force is available online at available online at www.
rdiosource.org/ACC/About-ACC/Leadership/Guidelines-and-
ocuments-Task-Forces.aspx. The work of the writing com-
ittee was supported exclusively by the ACCF and AHA
nd the other partnering organizations) without commercial
pport. Writing committee members volunteered their time
r this effort. Meetings of the writing committee were
nfidential and attended only by committee members and
aff.
.3. Review of Literature and
xisting Data Definitions
he nomenclature used in this document to designate specific
AVDs, including lower extremity PAD, AAA, renal and
esenteric artery disease, and extracranial carotid artery
sease, is derived from an AHA conference proceeding (2).
he “Peripheral Atherosclerotic Vascular Disease Data Stan- perds” are intended to provide data elements that parallel and
mplement existing data fields previously reported in ACCF
d AHA data standards documents (6–11), along with those
ed as fields within existing registries, such as those devel-
ed by the ACC National Cardiovascular Disease Registry
2). The writing committee also reviewed the “2007 ACC/
HA Methodology for the Development of Clinical Data
tandards” (13), the reporting standards formulated by the
ociety for Vascular Surgery/International Society for Car-
ovascular Surgery; the “AHA Guidelines for the Reporting
Renal Artery Revascularization in Clinical Trials” (14); the
ational Heart, Lung, and Blood Institute CLEVER (Claudi-
tion: Exercise Vs Endoluminal Revascularization) Study
5,16); CORAL (Cardiovascular Outcome in Renal Athero-
lerotic Lesions) trials (17,18); National Institute of Neuro-
gical Disorders and Stroke Common Data Elements (19);
d the AHA Get With The Guidelines–Stroke Program (20).
.4. Defining Data Elements
he definitions of the data elements developed by the writing
mmittee are broad enough for use in various aspects of data
llection but specific enough to promote uniform and sim-
ified interpretation of data. Some elements will require an
ditional level of specificity by the end user for implemen-
tion, which is beyond the scope of this document. Data
finitions were linked whenever possible to the evidence-
sed national guidelines.
To ensure consistency across ACCF/AHA data standards,
e writers used existing ACCF/AHA definitions. The writing
mmittee chose not to develop an all-inclusive list of every
ssible data element that may be used for all aspects of
AVD. Rather, the committee focused on common elements
at cross vascular specialty disciplinary boundaries. It is
ticipated that some data definitions and elements will
ed further delineation, likely by subspecialty societies and
oups. The purpose of this document is to attempt to
rmonize as many common data fields as possible.
.5. Relation to Other Standards
s previously noted, the writing committee reviewed other
andards, including those developed for heart failure, atrial
brillation, electrophysiology, acute coronary syndromes,
d cardiac imaging. It was thought that members of the
riting committee possessed the key levels of expertise
eded to address issues relating to PAVD in a consistent
anner.
.6. Consensus Development
hese ACCF/AHA data standards, like other documents
veloped by the ACCF and AHA, were developed and
ritten as a team effort based on the judgments of experts.
he writing committee met 10 times, by telephone and in
rson, to define and refine the data elements. Throughout the
ocess, consensus was developed through extensive in-
rson discussion, teleconferences, and e-mail messages.
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ement Name Definition
mographics
Sex Indicate the patient’s sex at birth. Choose 1 of the following:
● Male
● Female
Date of birth Indicate the patient’s date of birth (mo/d/y).
Race Indicate the patient’s race as determined by the patient/family:
● American Indian or Alaska Native
● Asian
● Black or African American
● Native Hawaiian or Other Pacific Islander
● White
● Other (specify)
Hispanic ethnicity Is the patient Spanish, Hispanic, or Latino? Choose 1 of the following:
● Yes
● No
Patient zip code Indicate the zip code of the residence where the patient typically lives.
Institution Coded identification and location of the healthcare facility.
Insurance payer Indicate the patient’s primary insurance payer for this admission. Choose 1 of the following:
● Government: Refers to patients who are covered by government-reimbursed care. In the United States this
includes
— Medicare
— Medicaid (including all state or federal Medicaid-type programs)
— Veterans Health Administration
— Department of Defense
— Other federal group (specify)
● Commercial: Refers to all indemnity (fee-for-service) carriers and PPOs
● HMO: Refers to a health maintenance organization characterized by coverage that provides healthcare services for
members on a prepaid basis
● None: Refers to patients with limited or no health insurance; thus, the patient is the payer regardless of ability to
pay. Only mark “None” when “self” or “none” is denoted as the first insurance in the medical record.
esentation to Healthcare Facility
Presentation to healthcare facility Indicate the date and time the patient presented to the healthcare facility.
Type of encounter ● Emergency admission for stroke
● Emergency admission for TIA
● Emergency admission for limb ischemia
● Emergency admission for other cardiovascular problem
● Emergency admission for noncardiovascular problem
● Planned admission for evaluation/treatment of carotid artery disease
● Planned admission for evaluation/treatment of PAD
● Planned admission for evaluation/treatment of aortic aneurysm
● Planned admission for evaluation/treatment of renal/mesenteric artery disease
● Planned admission for other cardiovascular problem
● Planned admission for noncardiovascular problem
● Regularly scheduled outpatient visit
● Urgent or other unscheduled outpatient visit
Primary reason for encounter ● Symptoms related to carotid artery disease
● Symptoms related to PAD
● Symptoms related to aortic aneurysmal disease
● Symptoms related to renal artery disease
● Symptoms related to mesenteric artery disease
● Symptoms related to other cardiovascular disease
● Noncardiovascular symptoms
Admission location ● ICU/stroke unit
● Step-down unit
● Unmonitored hospital floor
● Observation/holding unit in emergency department
● Outpatient
(Continued)
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Means of transport ● Self/family/friend/caregiver
● Taxi/public transportation
● Ambulance
● Mobile ICU
● Air or ambulance transfer from another facility
Location of encounter (21) Indicate the location of encounter:
● Air or ambulance transfer from another facility
● Caregiver office: primary care or specialist
● Urgent care facility
● Inpatient hospital
● Outpatient hospital
● Emergency department
● Ambulatory surgery center
● Inpatient rehabilitation facility
● SNF
● Mobile unit
tient History
Risk Factors for Atherosclerosis
Hypertension Indicate if the patient has a current or previous diagnosis of hypertension as defined by any of the following:
● History of hypertension diagnosed and treated with medication, diet, and/or exercise
● On at least 2 occasions, documented blood pressure 140 mm Hg systolic and/or 90 mm Hg diastolic in patients
without diabetes or chronic kidney disease; 130 mm Hg systolic or 80 mm Hg diastolic in patients with
diabetes or chronic kidney disease
● Currently on pharmacological therapy for treatment of hypertension
More than 1 of the above may apply. The year of onset (first diagnosis) may be helpful.
Diabetes (22) History of diabetes diagnosed and/or treated by a physician. The American Diabetes Association criteria include
documentation of the following:
● Hemoglobin A1c 6.5%; or
● Fasting plasma glucose 126 mg/dL (7.0 mmol/L); or
● Two-hour plasma glucose 200 mg/dL (11.1 mmol/L) during an oral glucose tolerance test; or
● In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose
200 mg/dL (11.1 mmol/L).
This does not include gestational diabetes.
Indicate the following:
1. Type 1 or type 2 diabetes
2. Year of onset (if known)
Dyslipidemia Current or previous diagnosis of dyslipidemia per the National Cholesterol Education Program criteria (23), defined as
any 1 of the following:
● Total cholesterol 200 mg/dL (5.18 mmol/L)
● LDL 130 mg/dL (3.37 mmol/L)
● HDL 40 mg/dL (1.04 mmol/L) in men and 50 mg/dL (1.30 mmol/L) in women
Treatment is also initiated if LDL is 100 mg/dL (2.59 mmol/L) in patients with known coronary artery disease or
CHD equivalent, and this would qualify as hypercholesterolemia.
History of smoking (24) History confirming cigarette smoking in the past. Choose from the following categories:
● Current every day smoker
● Current some days smoker
● Former smoker
● Never smoker
● Smoker, current status unknown
● Unknown if ever smoked
For current or former smokers, total pack years may be useful.
Alcohol consumption Specify the patient’s history of alcohol consumption. Choose from the following categories:
● None
● 1 alcoholic drinks/wk
● 2–7 alcoholic drinks/wk
● 8–13 alcoholic drinks/wk
● 14–20 alcoholic drinks/wk
● 21 alcoholic drinks/wk
(Continued)
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ement Name Definition
Specify alcohol-dependency history. Choose all that apply:
Documented alcohol dependency
Medical sequelae of alcohol consumption (alcoholic hepatitis, cirrhosis, alcohol neuropathy,
Wernicke-Korsakoff syndrome)
Treatment for alcohol dependency
For patients with alcohol dependency, note treatment for dependency, cessation of use, or continued use.
Illicit drug use Indicate history of current, recent, or remote abuse of any illicit drug (e.g., cocaine, methamphetamine, marijuana)
or controlled substance. Choose 1 of the following:
● Yes
● No
Evidence of Atherosclerosis
History of MI The term myocardial infarction should be used when there is evidence of myocardial necrosis in a clinical setting
consistent with myocardial ischemia. Under these conditions, any 1 of the following criteria meets the diagnosis
for MI:
● Detection of rise and/or fall of cardiac biomarkers (preferably troponin) with at least 1 value above the
99th percentile of URL together with evidence of myocardial ischemia with at least 1 of the following:
— Symptoms of ischemia
— Electrocardiographic changes indicative of new ischemia (new ST-T changes or new LBBB)
— Development of pathological Q waves in the ECG
— Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality
● Sudden unexpected cardiac death, involving cardiac arrest, often with symptoms suggestive of myocardial
ischemia, and accompanied by presumably new ST elevation or new LBBB and/or evidence of fresh thrombus by
coronary angiography a time before the appearance of cardiac biomarkers in the blood.
● For PCI in patients with normal baseline indicative of periprocedural myocardial necrosis. By convention, increases
of biomarkers 399th percentile URL have been designated as PCI-related MI. A subtype related to a
documented stent thrombosis is recognized.
● For CABG in patients with normal baseline troponin values, elevations of cardiac biomarkers above the
99th percentile URL are indicative of periprocedural myocardial necrosis. By convention, increases of biomarkers
599th percentile URL plus either new pathological Q waves or new or imaging evidence of new loss of viable
myocardium have been designated as defining CABG-related MI.
● Pathological findings of an acute MI.
MI within the past 6 wk Indicate if the patient had an MI within 6 wk prior to the index procedure as evidenced by the following:
1. Acute MI (7 d) manifested as a rise and fall of cardiac biomarkers (preferably troponin) with at least 1 value
above the range of normal for your laboratory (above the 99th percentile of the URL) together with evidence of
myocardial ischemia with at least 1 of the following:
a. Ischemic symptoms
b. Electrocardiographic changes indicative of new ischemia (new ST-T and/or T-wave changes or new LBBB)
c. Development of pathological Q waves on the ECG
d. Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality
2. Recent MI (7 d) manifested by
a. An MI meeting the criteria for an acute MI as documented in the medical record, or
b. By any 1 of the following:
1. Development of new pathological Q waves with or without symptoms
2. Imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract
3. In the absence of a nonischemic cause
History of angina History of angina may include
● Stable angina
— Indicate CCS class
● Unstable angina
● Prior angina; currently asymptom1atic
Dates should be sought for the onset of either stable or unstable angina.
Previous CABG surgery Indicate history of prior CABG surgery, including the date or year of surgery.
The total number of CABG procedures and the year of the most recent procedure may be helpful.
Previous PCI Prior PCI of any type (balloon angioplasty, atherectomy, stent, or other)Total number of PCI procedures and dates
(years)
(Continued)
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History of PAD Indicate if the patient has a history of lower extremity PAD (from iliac to tibials). Excludes renal, coronary, cerebral,
and mesenteric vessels and aneurysm. Major symptoms can include
● Asymptomatic (confirmed by noninvasive diagnostic test)
● Claudication relieved by rest
● Ischemic rest pain
● Tissue loss (including ischemic ulcer and/or gangrene)
● Amputation for critical limb ischemia
● Vascular reconstruction, bypass surgery, or percutaneous revascularization in the arteries of the lower extremities
● Positive noninvasive test (e.g., ABI 0.90, ultrasound, MR or CT imaging demonstrating 50% diameter stenosis
in any peripheral artery, ie, aorta, iliac, femoral, popliteal, tibial, peroneal)
History of aortic aneurysm Indicate if the patient has a history of aortic aneurysm. This can include
● Thoracic aneurysm
● Thoracoabdominal aneurysm
● AAA
Confirmed by ultrasound, CT, and/or MR imaging.
History of renal or
mesenteric artery disease
Indicate if the patient has a history of renal or mesenteric artery disease. This can include an abnormal imaging
study such as duplex ultrasonography, MRA, CTA, or catheter-based contrast angiography demonstrating 50%
diameter stenosis in the renal artery, celiac trunk, SMA, or IMA.
TIA (25) Indicate if the patient has a documented history of TIA consisting of a transient episode of neurological dysfunction
caused by focal brain, spinal cord, or retinal ischemia without acute infarction.
Note the following:
● Right retinal
● Right hemispheric
● Left retinal
● Left hemispheric
● Vertebrobasilar
● Unknown distribution
Prior stroke Indicate whether the patient has a history of stroke, which is defined as an acute episode of neurological dysfunction
caused by focal or global brain, spinal cord, or retinal vascular injury as a result of hemorrhage or infarction.
If present, record the type of stroke (26,27):
● Ischemic
● Intracerebral hemorrhage
● Subarachnoid hemorrhage
● Unknown
If ischemic, list the most likely etiologies:
● Large-artery atherosclerosis of the extracranial vessels (e.g., carotid)
● Large-artery atherosclerosis of the intracranial vessels (e.g., middle cerebral artery stenosis)
● Cardioembolism
● Small-vessel occlusion (lacunar)
● Ischemic stroke of other determined etiology (e.g., arterial dissection)
● Ischemic stroke of undetermined etiology
Congestive Heart Failure
CHF Indicate if the patient has a previous history of CHF. This includes a previous hospital admission with a principal
diagnosis of CHF.
CHF is defined as documentation or report of any 2 of the following Framingham major criteria of heart failure:
orthopnea/paroxysmal nocturnal dyspnea; or the description of rales, jugular venous distention, hepatojugular reflux,
S3 gallop, or pulmonary edema on chest x-ray; or 1 of the major criteria plus 2 Framingham minor criteria, including
dyspnea on exertion, nocturnal cough, ankle edema, pleural effusion, or tachycardia. A low ejection fraction without
clinical evidence of heart failure does not qualify as heart failure.
Include the year of onset if known.
NYHA classification scale (28) To classify symptoms or signs in patients with suspected or presumed heart failure per the NYHA classification
scale:
● Class I: without limitations of physical activity. Ordinary physical activity does not cause undue fatigue,
palpitations, or dyspnea.
● Class II: slight limitation of physical activity. The patient is comfortable at rest. Ordinary physical activity results in
fatigue, palpitations, or dyspnea.
● Class III: marked limitation of physical activity. The patient is comfortable at rest. Less than ordinary activity
causes fatigue, palpitations, or dyspnea.
● Class IV: inability to carry on any physical activity without discomfort. Heart failure symptoms are present even at
rest or with minimal exertion.
(Continued)
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Pulmonary insufficiency Indicate if the patient has a history of pulmonary insufficiency. Pulmonary insufficiency is defined as Pao2 of
60 mm Hg while breathing air or Paco2 of 50 mm Hg.
Chronic kidney disease (29) Current or previous history of chronic kidney disease. Chronic kidney disease is defined as either kidney damage or
GFR 60 mL/min/1.73 m2 for 3 mo. Kidney damage is defined as pathologic abnormalities or markers of damage,
including abnormalities in blood or urine tests or imaging studies.
Indicate the patient’s stage of disease:
● Stage 0: No known kidney disease
● Stage 1: Kidney damage with normal or high GFR 90 mL/min/1.73 m2
● Stage 2: Kidney damage with mildly decreased GFR—60–89 mL/min/1.73 m2
● Stage 3: Moderately decreased GFR—30–59 mL/min/1.73 m2
● Stage 4: Severely decreased GFR—15–29 mL/min/1.73 m2
● Stage 5: Kidney failure—GFR 15 mL/min/1.73 m2 or on dialysis
Note: GFR may be estimated using the serum creatinine MDRD formula:
eGFR186 (serum creatinine)1.154 (age)0.203 (0.742 [if female]) (1.210 [if black])
Year of onset (first diagnosis) may be helpful.
tient Assessment:
ysical Evaluation
Height Patient’s height in centimeters. To be converted from conventional units if needed
Note: May be measured or reported by the patient.
Weight Patient’s measured actual weight in kilograms. To be converted from conventional units if needed
Note: Must be measured during encounter. It is advisable to standardize clothing worn (i.e., whether shoes are worn).
BMI BMI is calculated according to the following formula: the patient’s weight in kilograms, divided by height in meters
squared. Obesity is defined as a BMI 30 kg/m2.
Blood pressure (right and left arm) Systolic and diastolic blood pressure (mm Hg) in both the right and left arms recorded closest to the time of
presentation at the healthcare facility. The patient’s position (supine, sitting, other) may be noted.
Heart rate Number of heart beats over 1 min.
Note: Recorded closest to the time of presentation at the healthcare facility and/or on discharge (for inpatient).
Specify whether the heart rate is regular or irregular. Heart rate may be ascertained from the ECG or record of
physical examination.
Cardiac rhythm Indicate if the patient has any of the following:
● Normal sinus rhythm
● Atrial fibrillation
● Other
Complete vascular examination Carotid, upper, lower extremity pulses, auscultation of the neck for carotid bruits, auscultation of the abdomen and
femoral arteries for bruits, palpation of the abdomen and popliteal fossa for aneurysms
Complete cardiac examination Palpation and auscultation of the heart, assessing rate, rhythm, presence of murmur, presence of gallop (e.g., S3
suggesting left ventricular dysfunction; S4 suggesting noncompliant left ventricle), notation of location of point of
maximal intensity
Limb edema Note the presence/absence of lower extremity (less commonly, upper extremity) edema, including location, extent,
and pitting versus nonpitting.
boratory Testing
CBC Include RBC, WBC, and platelet counts: 1) value, 2) unit of measurement, 3) date, and 4) normal range
(upper limit of normal when appropriate)
Hemoglobin 1) value, 2) unit of measurement, 3) date, and 4) normal range (upper limit of normal when appropriate)
Hematocrit 1) value, 2) unit of measurement, 3) date, and 4) normal range (upper limit of normal when appropriate)
Glucose 1) value, 2) unit of measurement, 3) date, and 4) normal range (upper limit of normal when appropriate)
BUN 1) value, 2) unit of measurement, 3) date, and 4) normal range (upper limit of normal when appropriate)
Creatinine 1) value, 2) unit of measurement, 3) date, and 4) normal range (upper limit of normal when appropriate)
GFR Indicate estimated or actual GFR in milliliters per minute per 1.73 meters squared.
Sodium 1) value, 2) unit of measurement, 3) date, and 4) normal range (upper and lower limit of normal when appropriate)
Potassium 1) value, 2) unit of measurement, 3) date, and 4) normal range (upper and lower limit of normal when appropriate)
Hemoglobin A1C 1) value, 2) unit of measurement, 3) date, and 4) normal range (upper limit of normal when appropriate)
Prothrombin time Measured in seconds. Report INR as ratio.
Partial thromboplastin time Indicate whether activators used (aPTT) or not (PTT). Measured in seconds.
Total cholesterol 1) value, 2) unit of measurement, 3) date, and 4) normal range (upper limit of normal when appropriate)
(Continued)
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LDL 1) value, 2) unit of measurement, 3) date, and 4) normal range (upper limit of normal when appropriate)
HDL 1) value, 2) unit of measurement, 3) date, and 4) normal range (upper limit of normal when appropriate)
Triglycerides 1) value, 2) unit of measurement, 3) date, and 4) normal range (upper limit of normal when appropriate)
hs-CRP 1) value, 2) unit of measurement, 3) date, and 4) normal range (upper limit of normal when appropriate)
ESR 1) value, 2) unit of measurement, 3) date, and 4) normal range (upper limit of normal when appropriate)
Calcium 1) value, 2) unit of measurement, 3) date, and 4) normal range (upper and lower limit of normal when appropriate)
Phosphorus 1) value, 2) unit of measurement, 3) date, and 4) normal range (upper and lower limit of normal when appropriate)
Magnesium 1) value, 2) unit of measurement, 3) date, and 4) normal range (upper and lower limit of normal when appropriate)
TSH 1) value, 2) unit of measurement, 3) date, and 4) normal range (upper limit of normal when appropriate)
BNP or N-terminal BNP 1) value, 2) unit of measurement, 3) date, and 4) normal range (upper limit of normal when appropriate)
AST 1) value, 2) unit of measurement, 3) date, and 4) normal range (upper limit of normal when appropriate)
ALT 1) value, 2) unit of measurement, 3) date, and 4) normal range (upper limit of normal when appropriate)
CK The upper limit of normal of total CK as defined by individual hospital laboratory standards. Units of CK and type of
units should be noted (e.g., IU, ng/dL, kCat/L).
All CK values during hospitalization should be noted; include units, date, and time.
Troponin Indicate which type: T or I.
Indicate the upper limit of normal (usually the 99th percentile of a normal population) and units (e.g., ng/dL).
All troponin T or I values during hospitalization should be noted; include units, date, and time.
Homocysteine 1) value, 2) unit of measurement, 3) date, and 4) normal range (upper limit of normal when appropriate)
Vitamin B12 1) value, 2) unit of measurement, 3) date, and 4) normal range (upper limit of normal when appropriate)
Folate 1) value, 2) unit of measurement, 3) date, and 4) normal range (upper limit of normal when appropriate)
Prothrombin 20210 gene mutation 1) value, 2) unit of measurement, 3) date, and 4) normal range (upper limit of normal when appropriate)
Protein C activity 1) value, 2) unit of measurement, 3) date, and 4) normal range (upper limit of normal when appropriate)
Protein S activity 1) value, 2) unit of measurement, 3) date, and 4) normal range (upper limit of normal when appropriate)
Antithrombin III 1) value, 2) unit of measurement, 3) date, and 4) normal range (upper limit of normal when appropriate)
Anticardiolipin antibody 1) value, 2) unit of measurement, 3) date, and 4) normal range (upper limit of normal when appropriate)
Lupus anticoagulant 1) value, 2) unit of measurement, 3) date, and 4) normal range (upper limit of normal when appropriate)
rrent Pharmacologic Therapy to
anage Cardiovascular Disease
Antiplatelet Drugs
Aspirin Note specific dose.
Clopidogrel Note specific dose.
Prasugrel Note specific dose.
Other P2Y12 antagonists Note specific drug and dose.
Dipyridamole Note specific dose.
Others Note specific drug and dose.
Anticoagulant Drugs
Unfractionated heparin Note specific dose.
Low–molecular-weight heparin Note specific drug and dose.
Fondaparinux Note specific dose.
Other factor Xa inhibitor Note specific drug and dose.
Direct thrombin inhibitor Note specific drug and dose.
Warfarin Indicate whether this drug has been prescribed; note INR.
Others Note specific drug and dose.
Drugs to Control
Cardiovascular Risk Factors
Antihypertensive drugs Note specific drug and dose.
Statins and lipid-control agents Note specific drug and dose.
Drugs for diabetes Note specific drug and dose.
Drugs to aid in
smoking cessation
Note specific drug and dose.
(Continued)
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hysicians; American Association of Cardiovascular and Pul-
onary Rehabilitation; American Academy of Neurology;
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r Cardiovascular Magnetic Resonance; and Vascular Disease
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ne 2011; American Association of Cardiovascular and Pulmo-
ry Rehabilitation, American Academy of Neurology, Ameri-
n Diabetes Association, Society of Atherosclerosis Imaging
d Prevention, Society of Cardiovascular Computed Tomogra-
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The writing committee anticipates that these data standards
ill require review and updating, as with the ACCF/AHA
idelines, performance measures, and appropriate use crite-
ble 1. Continued
ement Name Definition
Drugs for Coexisting
Cardiovascular Conditions
Antiarrhythmic drugs Note specific drug and dose.
Heart failure medications Note specific drug and dose.
Drugs for symptoms of PAD Note specific drug and dose.
Noncardiovascular medications Note the specific drug and dose.
her Elements Related to
armacological Therapy to
anage Cardiovascular Disease
Medication allergy Specify the medication and type of
Medication side effect Describe the side effect and wheth
AAA indicates abdominal aortic aneurysm; ABI, ankle brachial index; ALT, ala
inotransferase; BMI, body mass index; BNP, B-type natriuretic peptide; BUN, b
S, Canadian Cardiovascular Society; CHD, coronary heart disease; CHF,
ectrocardiogram; ESR, erythrocyte sedimentation rate; GFR, glomerular filtration
gh-sensitivity C-reactive protein; ICU, intensive care unit; IMA, inferior mesent
w-density lipoprotein; MDRD, modification of diet in renal disease; MI, myocardi
w York Heart Association; PAD, peripheral artery disease; PCI, percutaneous co
e; RBC, red blood cell; SMA, superior mesenteric artery; SNF, skilled nursing
ference limit; and WBC, white blood cell.a. At the anniversary of publication, the writing committee suill review the data standards to ascertain whether modifica-
ons should be considered.
.8. Intended Use
he writing committee anticipates that the “Key Data Ele-
ents and Definitions for Peripheral Atherosclerotic Vascular
isease” will prove useful in several settings:
Clinical programs in which providers and health plans
work in concert to achieve optimal use of procedures
pertinent to PAVD. Data standards will assist in the
development of structured reporting systems and the
organization and design of electronic medical information
systems, including clinical database and decision support
tools.
Clinical research, including prospective registries and
randomized controlled trials. Meta-analyses will be par-
ticularly strengthened by the use of standardized data for
key variables.
Quality assessment/performance measurement. Data stan-
dards will especially facilitate interpretation for nonmed-
ical users, including payers, regulators, and consumers.
. PAVD Data Standard Elements
nd Definitions
.1. General Table of Data Elements
he general elements listed in Table 1 are applicable to all of
e PAVDs included in this document. These include demo-
aphic elements, such as sex, age, race, ethnicity, and payer
formation; elements related to the patient’s presentation,
ch as the primary reason for the encounter and its location;
sk factors for atherosclerosis, such as hypertension, dyslip-
emia, diabetes mellitus, and cigarette smoking; and evi-
nce of previously established atherosclerotic conditions,
.
edication was stopped.
inotransferase; aPTT, activated partial thromboplastin time; AST, aspartate
ea nitrogen; CABG, coronary artery bypass graft; CBC, complete blood count;
ive heart failure; CK, creatine kinase; CT, computed tomography; ECG,
DL, high-density lipoprotein; HMO, health maintenance organization; hs-CRP,
ry; INR, international normalized ratio; LBBB, left bundle-branch block; LDL,
tion; MR, magnetic resonance; MRA, magnetic resonance angiography; NYHA,
ntervention; PPO, preferred provider organization; PTT, partial thromboplastin
TIA, transient ischemic attack; TSH, thyroid stimulating hormone; URL, upperreaction
er the m
nine am
lood ur
congest
rate; H
eric arte
al infarc
ronary i
facility;ch as coronary artery disease, lower extremity PAD,
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tient Assessment: Signs and Symptoms
Asymptomatic The patient has no symptoms of claudication, no symptoms of ischemic pain, and no limitation in walking distance.
Claudication: characteristics Indicate claudication as determined by the discomfort:
● Exertional
● Reproducible
● Resolves within 10 min of rest
Claudication: description Describe the discomfort. Choose all that apply:
● Cramping
● Aching
● Fatigue
● Other
Claudication: location Indicate the limb (right leg, left leg, both) with discomfort and the location of the discomfort. Choose all that apply:
● Buttock
● Hip
● Thigh
● Calf
● Foot
Claudication: walking When describing walking, indicate the following:
● Pain-free walking distance (ft/m/blocks)
● Maximum walking distance (ft/m/blocks)
● Typical walking speed
— Slow
— Normal
— Fast
● Flat surface versus incline
Claudication: onset of symptoms Indicate the following:
● Date of onset
● Duration of symptoms
Claudication: stability of symptoms Indicate if symptoms
● Improved
● Stabilized
● Worsened
Atypical symptoms Describe the characteristics of atypical symptoms.
Ischemic rest pain Indicate if the pain and discomfort
● Are characterized by aching or burning at rest or with elevation
● Are relieved by dependency
● Interfere with sleep
Also indicate the following:
● Location (right or left leg or both)
— Forefoot
— Toes
● Date of onset
● Duration of symptoms
● Frequency of occurrence
— Intermittent
— Constant
Tissue loss To report a nonhealing wound, indicate the following:
● Location
● Onset/duration
ute Limb Ischemia
Characteristics Indicate if there is sudden onset of
● Pain
● Paresthesia
Location Indicate the specific location of pain.
Symptom onset Indicate the onset and duration of symptoms.
(Continued)
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tient Assessment: Physical Evaluation
Pulses Indicate the characteristics of pulses in the following locations:
● Femoral
● Popliteal
● Dorsalis pedis
● Posterior tibial
Indicate if pulses are:
● 0: Absent
● 1: Diminished
● 2: Normal
● 3: Bounding
Bruits Indicate the presence or absence of bruits on auscultation in the following:
● Carotid
● Abdominal
● Femoral
● Subclavian
Elevation pallor Indicate the presence of pallor of the forefoot after elevating the leg 60° for 1 min.
Reperfusion delay Reperfusion delay (40 s)
Dependent rubor Indicate if rubor of the foot is present when held in dependence after an elevation pallor maneuver.
Acute limb ischemia Acute limb ischemia is characterized by
● Pallor
● Pulselessness
● Poikilothermia
● Paralysis
— One of the following categories should be assigned:
Œ I: Viable—Limb is not immediately threatened; no sensory loss; no muscle weakness; audible arterial and
venous Doppler
Œ II: Threatened—Mild to moderate sensory or motor loss; inaudible arterial Doppler; audible venous Doppler
Œ III: Irreversible—Major tissue loss or permanent nerve damage inevitable; profound sensory loss, anesthetic;
profound muscle weakness or paralysis (rigor); inaudible arterial and venous Doppler
Tissue loss (ischemic wound or
gangrene): characteristics
Tissue loss is characterized by
● Dryness
● Necrosis
● Granulation
Tissue loss (ischemic wound or
gangrene): affected limb
Indicate the affected extremity/extremities. Choose 1 of the following:
● Left
● Right
● Bilateral
Tissue loss (ischemic wound or
gangrene): location
Specify the location of tissue loss. Choose all that apply:
● Distal aspect of leg or foot
● Over bony prominence
● Toe
● Others
Tissue loss (ischemic wound or
gangrene): wound area
Indicate the measured area of the wound in centimeters.
Tissue loss (ischemic wound or
gangrene): infection
Indicate the presence or absence of infection. Choose 1 of the following:
● Yes
● No
Tissue loss (ischemic wound or
gangrene): type
Indicate the type of tissue loss. Choose 1 of the following:
● Minor: nonhealing ulcer, focal gangrene with diffuse pedal ischemia
● Major: extending above transmetatarsal level; functional foot no longer salvageable
Tissue loss (ischemic wound or
gangrene): depth/Wagner grade
Indicate the Wagner grade of the wound/gangrene. Choose 1 of the following:
● Grade 0: Pre- or postulcerative lesion
● Grade 1: Partial/full thickness ulcer
● Grade 2: Probing to tendon or capsule
● Grade 3: Deep with osteitis
● Grade 4: Partial foot gangrene
● Grade 5: Whole foot gangrene
(Continued)
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agnostic Testing:
ninvasive Procedures
Ankle Brachial Index/Toe Brachial Index
Date of procedure Indicate the date the procedure was performed (mo/d/y).
Ankle systolic pressure Indicate the ankle systolic pressure of the right and left legs and whether it is recorded from the posterior tibial or
dorsalis pedis arteries.
ABI value Indicate the ABI value for each leg. Choose 1 of the following:
● Normal (ABI 1.00–1.40)
● Abnormal (ABI 0.90)
● Borderline (ABI 0.91–0.99)
● Noncompressible arteries (ABI 1.40)
Great toe systolic pressure Indicate the right and left great toe systolic pressures.
TBI value Indicate the TBI value for each leg. A TBI value of 0.7 is abnormal.
Exercise Testing: Treadmill Exercise
Date of procedure Indicate the date exercise testing was performed (mo/d/y).
Protocol Specify the symptom-limited exercise protocol used (constant load/graded).
Postexercise ankle pressure
and/or ABI
Indicate if immediate postexercise ankle pressure and/or ABI measurement were performed. Choose 1 of the
following:
● Yes. If so, indicate value.
● No
Walking time Indicate the following walking time in minutes:
● Claudication onset time
● Peak walking time
Distance Indicate the walking distance in meters or feet:
● Claudication-onset walking distance
● Peak walking distance
METS 1 MET is defined as 3.5 mL O2 · kg
1 · min1. Indicate METS at peak exercise.
Alternative method A 6-min walk is the distance walked in 6 min on flat surface using standardized measurement procedures.
It is reported in meters or feet.
Segmental Pressure Examination
Date of examination Indicate the date the segmental pressure examination was performed (mo/d/y).
Segmental pressure measurements ● Right and left brachial pressures
● Right and left thigh pressures
● Right and left low thigh pressures
● Right and left thigh calf pressures
● Right and left dorsalis pedis pressures
● Right and left posterior tibial pressures
Indicate if there is a 20 mm Hg drop between the contiguous segments of the same leg, which can suggest the
location of stenosis.
Pulse Volume Recording
Date of recording Indicate the date PVR was taken (mo/d/y).
Amplitude reduction Indicate the leg and location of PVR:
● Right/left high thigh
● Right/left low thigh
● Right/left calf
● Right/left ankle
● Right/left metatarsal
Choose 1 of the following to describe pulse wave amplitude:
● Normal
● Abnormal
● Mildly reduced
● Moderately reduced
● Severely reduced
Transcutaneous Oxygen Pressure
Date of measurement Indicate the date of measurement (mo/d/y).
TcPo2 measured Measurement of the pressure of oxygen on the surface of the skin. Indicate the following:
● Right foot
● Left foot
Value of TcPo2 Indicate the TcPo2 value in the right foot and left foot.
(Continued)
Ta
El
308 Creager et al. JACC Vol. 59, No. 3, 2012
ACCF/AHA PAVD Data Standards January 17, 2012:294–357ble 2. Continued
ement Name Definition
Duplex Ultrasound
Date of procedure Indicate the date the procedure was performed (mo/d/y).
Artery imaged Indicate the artery imaged. Choose all that apply:
● Aorta
● Right/left CIA
● Right/left EIA
● Right/left common femoral artery
● Right/left proximal profunda femoris artery
● Right/left superficial femoral artery
● Right/left popliteal artery
● Right/left tibioperoneal trunk
● Right/left anterior tibial artery
● Right/left posterior tibial artery
● Right/left peroneal artery
Peak systolic velocity Specify for
● Aorta
● Right/left CIA
● Right/left EIA
● Right/left common femoral artery
● Right/left proximal profunda femoris artery
● Right/left superficial femoral artery
● Right/left popliteal artery
● Right/left tibioperoneal trunk
● Right/left anterior tibial artery
● Right/left posterior tibial artery
● Right/left peroneal artery
Category of stenosis Specify for
● Aorta
● Right/left CIA
● Right/left EIA
● Right/left common femoral artery
● Right/left proximal profunda femoris artery
● Right/left superficial femoral artery
● Right/left popliteal artery
● Right/left tibioperoneal trunk
● Right/left anterior tibial artery
● Right/left posterior tibial artery
● Right/left peroneal artery
Indicate the category of stenosis (30):
● Normal
● 1%–49%
● 50%–99%
● Occlusion
Bypass graft Indicate location of proximal and distal anastomosis and type (e.g., in situ saphenous vein, reverse saphenous vein, PTFE).
Peak systolic velocity of
bypass graft
Indicate peak systolic velocity at proximal anastomosis, along conduit, and at distal anastomosis.
Ratios of peak systolic velocities
along bypass graft
Indicate ratio of peak systolic velocity of 2 contiguous segments at proximal anastomosis, along conduit, and at
distal anastomosis.
Category of bypass graft stenosis Bypass graft stenosis percentage. Indicate location and choose 1 of the following:
● 0%–49%
● 50%–99%
● Occluded
Magnetic Resonance Angiography
Date of procedure Indicate the date the procedure was performed (mo/d/y).
Contrast use Indicate if gadolinium was used. Choose 1 of the following:
● Yes
● No
(Continued)
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Artery imaged Indicate the artery imaged. Choose all that apply:
● Abdominal aorta
● Right/left iliac (common, internal, external) artery
● Right/left femoral (common, superficial, deep) artery
● Right/left popliteal (above knee, below knee, both) artery
● Right/left tibial/peroneal (anterior tibial, posterior tibial, peroneal) arteries
Lesion location Specify the location of the lesion.
Artery stenosis Indicate the severity of stenosis by quantitative analysis using the formula
100(1minimum lumen diameter)/maximum diameter of reference segment
Reconstitution Indicate if reconstitution was seen. Choose 1 of the following:
● Yes
● No
CT Angiography
Date of procedure Indicate the date the procedure was performed (mo/d/y).
Contrast used Indicate the type of contrast used. Choose 1 of the following:
● Ionic contrast
● Nonionic contrast; specify:
— Monomer
— Dimer
Contrast volume Indicate the volume of contrast used in milliliters.
Slice thickness Indicate the slice thickness in millimeters.
Format: raw images Indicate if raw images were reviewed. Choose 1 of the following:
● Yes
● No
Format: reconstructed images Indicate if reconstructed images were reviewed. Choose 1 of the following:
● Yes. If yes, specify
— Shaded surface images
— Maximum intensity projection
● No
Artery imaged Indicate the artery imaged. Choose all that apply:
● Abdominal aorta
● Right/left iliac (common, internal, external) artery
● Right/left femoral (common, superficial, deep) artery
● Right/left popliteal (above knee, below knee, both) artery
● Right/left tibial/peroneal (anterior tibial, posterior tibial peroneal) arteries
Lesion location Specify the location of the lesion.
Calcification Indicate if calcification is present. If present, specify the location. Choose 1 of the following:
● None
● Mild
● Moderate
● Severe
Artery stenosis Indicate the severity of stenosis by quantitative analysis using the formula
100(1minimum lumen diameter)/maximum diameter of reference segment
Reconstitution Indicate if reconstitution was seen. Choose 1 of the following:
● Yes
● No
agnostic Testing: Invasive Procedures
Catheter Angiography
Date of procedure Indicate the date the procedure was performed (mo/d/y).
Operator name Last name, first, middle
Anesthesia Indicate the type of anesthesia used. Choose 1 of the following:
● General
● Local
— Indicate if sedation was used. Choose 1 of the following:
Œ Yes
Œ No
● Regional
— With sedation
— Without sedation
(Continued)
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Vascular access site Specify the vascular access site.
Contrast agent Indicate the contrast agent used:
● Iodinated
— Ionic
— Nonionic
Œ Monomer
Œ Dimer
● Noniodinated (CO2)
Contrast volume Specify the contrast volume given.
Field size Indicate the field size in centimeters or inches.
Frame rate Indicate the FPS.
Image type Indicate the image type. Choose 1 of the following:
● Cine
● Digital images
Digital subtraction Indicate if digital subtraction was done. Choose 1 of the following:
● Yes
● No
Fluoroscopy time Indicate total fluoroscopy time recorded to the nearest 0.10 min. The time recorded should include the total time
for the procedure.
Artery imaged Indicate the artery imaged. Choose all that apply:
● Abdominal aorta
● Right/left iliac (common, internal, external) artery
● Right/left femoral (common, deep, superficial) artery
● Right/left popliteal (above knee, below knee, or both) artery
● Right/left tibial/peroneal (anterior tibial, posterior tibial, peroneal) arteries
Lesion location Specify the location of the lesion (ostial, proximal third, middle third, and distal third).
Calcification Indicate if calcification is present. If present, specify the location.
Choose 1 of the following:
● None
● Mild
● Moderate
● Severe
Artery stenosis Indicate the severity of stenosis by quantitative analysis using the formula
100(1minimum lumen diameter)/maximum diameter of reference segment
Reconstitution Indicate if the artery is reconstituted by collaterals. Choose 1 of the following:
● Yes
— If yes, indicate level.
● No
Translesional pressure gradient Indicate the pressure measured proximal to the stenosis minus the pressure measured distal to the stenosis.
Also indicate the following:
● Baseline pressure gradient
— Systolic
— Mean
— Diastolic
● Enhanced (hyperemic, postvasodilator) pressure gradient
— Systolic
— Mean
— Diastolic
● Measurement timing
— Simultaneous
— Pullback
Complications Indicate any technical complications encountered during the diagnostic procedure: Choose all that apply:
● Pseudoaneurysm
● Atrioventricular fistula
● Hematoma
● Dissection
● Vessel thrombosis
● Vessel perforation
● Atheromatous embolization
(Continued)
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● Contrast nephropathy
● Contrast hypersensitivity
● Requirement of intervention to prevent permanent impairment/damage
armacological Therapy for
mptoms of Claudication
Cilostazol Indicate if cilostazol has been prescribed for the patient. Choose 1 of the following:
● Yes
— If yes, indicate the following:
Œ Dose
Œ Duration of treatment
● No
Pentoxifylline Indicate if pentoxifylline has been prescribed for the patient. Choose 1 of the following:
● Yes
— If yes, indicate the following:
Œ Dose
Œ Duration of treatment
● No
ercise Rehabilitation for
termittent Claudication
Exercise Program Assessment
Functional status/quality of life Document functional ability at initiation and completion of the exercise program based on the following:
● Claudication onset walking distance
● Peak walking distance
● METS achieved at peak exercise
● 6-min walking test
● Questionnaires
Total exercise time Document the total exercise time during the exercise session at initiation and completion of the exercise program.
Total rest time Document the total rest time spent during the exercise session at initiation and completion of the exercise program.
Walking time Document the duration of walking time at initiation and completion of the exercise program.
Exercise Prescription
Place Indicate the place where exercise is done. Choose 1 of the following:
● Supervised facility
● Home based
Mode of exercise Indicate the mode of exercise prescribed. Choose 1 of the following:
● Treadmill
— Indicate initial speed and grade
— Indicate final speed and grade
● Track walking
— Indicate initial speed
— Indicate final speed
● Cycling
— Indicate initial speed and watts
— Indicate final speed and watts
Progression Indicate the recommendation for progression of exercise.
Intensity level Indicate the recommended claudication pain intensity level before resting.
RPE Indicate the recommended range of RPE.
Duration of session Indicate the duration of the exercise session in minutes.
Frequency of session Indicate the number of days of exercise session per week
Duration of prescription Indicate how long the exercise prescription should be performed in number of sessions or number of weeks
erapeutic Procedures: Endovascular
d Open Surgical Revascularization
Endovascular
Date Indicate the date the procedure was performed (mo/d/y).
Operator name Last name, first, middle
Limb revascularized Indicate which limb was revascularized. Choose 1 of the following:
● Right
● Left
● Both
(Continued)
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Procedure Indicate the procedure performed. Choose 1 or more of the following:
● Balloon angioplasty
● Cutting balloon
● Stent
— Indicate if stent is drug eluting. Choose 1 of the following
Œ Yes
– If so, specify the type of drug-eluting stent.
Œ No
● Stent graft
● Atherectomy
● Laser
● Cryoplasty
Vessel Indicate the target vessel for revascularization. Choose all that apply:
● Aorta
● CIA
● EIA
● IIA
● Common femoral artery
● Superficial femoral artery
● Deep femoral artery
● Popliteal (above the knee)
● Popliteal (below the knee)
● Anterior tibial artery
● Posterior tibial artery
● Peroneal artery
● Pedal arteries
Manufacturer Indicate the manufacturer of the device.
Model Indicate the model number of the device.
Diameter Indicate the maximum diameter of the device in millimeters.
Length Indicate the maximum length of the device in millimeters.
Time arrived in catheterization lab Indicate the time of patient arrival in the catheterization lab in hours:minutes.
Last catheter removed Indicate the date (mo/d/y) and time (h:min) the last catheter was removed.
Thrombolytic agent Indicate the thrombolytic agent used. Specify the following:
● Specific thrombolytic agent used
● Route of delivery
● Dosage
● Duration of infusion
Antithrombotic agent Indicate the antithrombotic agent used. Specify the following:
● Specific antithrombotic agent used. Choose 1 of the following:
— Unfractionated heparin
— Low–molecular-weight heparin
— Fondaparinux
— Direct thrombin inhibitor
● Route of delivery
● Dosage
● Duration of infusion
Antiplatelet agent Indicate the antiplatelet agent used. Specify the following:
● Dosage
Closure device Indicate if a closure device was used. Choose 1 of the following:
● Yes. Specify the following:
— Manufacturer
— Model
● No
Contrast Indicate type of contrast used. Choose 1 of the following:
● Iodinated
— Ionic
— Nonionic
— Monomer
Œ Dimer
● Noniodinated (CO2)
(Continued)
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Device utilization Indicate the devices used for the procedure. Choose all that apply:
● Guidewires
● Guiding catheters
● Intravascular ultrasound
● Angioplasty balloons
● Cutting balloon
● Infusion catheter
● Laser catheter
● Thrombectomy device
● Atherectomy device
● Reentry device
● Thermal balloon
● EPD
● Stent
● Drug-eluting stent
● Stent graft
Technical outcome Indicate the technical outcome of the procedure. Specify the following:
● Postprocedure translesional gradient
● Residual percent stenosis
Technical complication Indicate any technical complications encountered during the procedure: Choose all that apply:
● Vessel perforation
● Embolization (loss of runoff vessel)
● Dissection
● Vasospasm
● Access site bleeding
Open Surgery
Date of procedure Indicate the date the procedure was performed (mo/d/y).
Operator name Last name, first, middle
Location Indicate which limb the procedure was done. Choose 1 of the following:
● Right
● Left
● Both
Procedure type Indicate the type of procedure performed. Choose 1 of the following:
● Primary/secondary
● Bypass
— Inflow/outflow
— Anatomic/extra-anatomic
● Endarterectomy
● Thrombectomy
● Graft revision
Proximal anastomotic site Indicate the proximal anastomotic site and side. Choose 1 of the following:
● Thoracic aorta
● Abdominal aorta
● CIA
● EIA
● Common femoral artery
● Proximal superficial femoral artery
● Distal superficial femoral artery
● Profunda femoral artery
● Proximal popliteal artery
● Distal popliteal artery
● Tibioperoneal artery
● Proximal anterior tibial artery
● Distal anterior tibial artery
● Proximal posterior tibial artery
● Distal posterior tibial artery
● Proximal peroneal artery
● Distal peroneal artery
● Dorsalis pedis/tarsal artery
(Continued)
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Distal anastomotic site Indicate the distal anastomotic site. Choose 1 of the following:
● CIA
● EIA
● Common femoral artery
● Proximal superficial femoral artery
● Distal superficial femoral artery
● Profunda femoral artery
● Proximal popliteal artery
● Distal popliteal artery
● Tibioperoneal artery
● Proximal anterior tibial artery
● Distal anterior tibial artery
● Proximal posterior tibial artery
● Distal posterior tibial artery
● Proximal peroneal artery
● Distal peroneal artery
● Dorsalis pedis/tarsal artery
Graft material Indicate the type of graft material used for the procedure. Choose 1 of the following:
● Autogenous
— Specify the harvest site. Choose 1 of the following:
Œ Left
Œ Right
— Specify the vein used. Choose 1 of the following:
Œ Great saphenous vein, in situ
Œ Great saphenous vein, nonreversed
Œ Great saphenous vein, reversed
Œ Arm vein
Œ Small saphenous vein
Œ Composite vein
Œ Vein patch
● Autogenous-prosthetic composite
● Prosthetic
— Specify the type. Choose 1 of the following:
Œ PTFE
Œ Heparin-coated PTFE
Œ Dacron
Œ Other (specify)
Graft diameter Specify graft diameter:
● Prosthetic
● Vein
Anesthesia Indicate type of anesthesia used. Choose 1 of the following:
● General
● Local
— Indicate if sedation was used. Choose 1 of the following:
Œ Yes
Œ No
● Regional
— Epidural
— Spinal
— Indicate if sedation was used. Choose 1 of the following:
Œ Yes
Œ No
Technical outcome Indicate the technical outcome of the procedure. Specify the following:
● Postprocedure translesional gradient
● Residual percent stenosis
Completion study Indicate the type of study performed after the procedure. Choose 1 of the following:
● Angiogram
● Duplex ultrasound
(Continued)
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Estimated blood loss Indicate the estimated amount of blood loss in milliliters.
Transfused blood products Indicate the blood products transfused to the patient. Choose all that apply:
● Auto transfused blood (specify volume used)
● Packed RBCs
● Fresh frozen plasma
● Platelets
● Other (specify)
Operative time Indicate the total time of the procedure in hours:minutes.
tcomes of Endovascular/
en Surgery Procedures
Time point Indicate the period at which outcome measures are assessed. Choose all that apply:
● Periprocedure (24 h)
● Procedure related (30 d)
● 3 mo
● 6 mo
● 1 y
Serious adverse event Indicate major clinical complications arising from the management or treatment of the disease.
Choose 1 of the following:
● Yes
— Specify the serious adverse event. Choose all that apply:
Œ Hospitalization/prolonged hospitalization
Œ Loss of limb or function of organ system
Œ Persistent or significant disability or incapacity
Œ Death
● No
Complications of
endovascular procedure
Indicate postoperative clinical events or conditions associated with the endovascular procedure.
Choose all that apply:
● Pseudoaneurysm
● AV fistula
● Hematoma
● Dissection
● Vessel thrombosis
● Vessel perforation
● Atheromatous embolization
● Contrast nephropathy
● Contrast hypersensitivity
● Infection
● Requirement of intervention to prevent permanent impairment/damage
Complications of open surgery Indicate complications of open surgery. Choose all that apply:
● Major complication
— Death
— Shock (cardiogenic or septic)
— MI
— Stroke (ischemic, hemorrhagic, unknown type)
— Renal failure
— Prolonged hospitalization
— Infection
— Coagulopathy
— Thrombosis
— Compartment syndrome
— Acute graft failure
● Minor complication (specify)
inical Outcomes
Limb-Related Outcomes
Time point Indicate the period at which outcome measures are assessed. Choose all that apply:
● 1 mo
● 3 mo
● 6 mo
● 1 y
(Continued)
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dy mass index, vital signs, and aspects of the cardiac and
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mplete blood count, renal and hepatic function tests, lipid
vels, cardiac enzymes, markers of inflammation, and tests for
ble 2. Continued
ement Name Definition
Limb-related outcomes: symptoms ● Claudication
— None
— Unchanged
— Improved
— Worsened
● Ischemic rest pain
● Ischemic tissue loss
● Amputation
Limb-related outcomes:
functional capacity
Walking ability
● Pain-free walking distance (in m
● Maximum walking distance (in
Functional status/quality of life
● Questionnaire assessment
— Community-based walking (P
— Generic health status: SF-36
— PAD-specific quality of life: V
● Patient anecdote
Noninvasive assessment of outcome ● Limb perfusion pressure and/or
● Graft scan
● Other imaging (CTA or MRA)
Procedure-related outcomes Patency
● Primary
● Assisted
● Secondary
Limb-related outcomes:
wound healing
Wound healing characteristics. Co
● Description of dressing
● 1-wk change in area
● 4-wk change in area
● Presence and amount of granu
● Presence of reepithelialization
● Presence of fibrin slough
Cardiovascular Outcomes
Cardiovascular outcomes New cardiovascular ischemic even
● Angina
● MI
● Coronary artery revascularizatio
● CHF
● TIA
● Stroke (ischemic, hemorrhagic,
● Carotid artery revascularization
● Death
ABI indicates ankle brachial index; CHF, congestive heart failure; CIA, commo
A, external iliac artery; EPD, embolic protection device; FPS, frame rate per seco
farction; MRA, magnetic resonance angiography; PAD, peripheral artery disea
e; RBC, red blood cell; RPE, rating of perceived exertion; SF-36, Short Form 3
ygen; and TIA, transient ischemic attack.herited and acquired thrombophilia. Additional general ele- tients include current pharmacotherapy, such as antiplatelet/
ticoagulant drugs, medications to treat atherosclerotic risk
ctors, and drugs for comorbid cardiovascular conditions.
.2. Lower Extremity PAD Table
f Data Elements
ower extremity PAD is defined as atherosclerotic disease
at affects the arteries supplying the legs (2). Affected blood
ssels may include the aorta and the iliac, femoral, popliteal,
bial, and peroneal arteries and their major branches. The
ta elements defined in Table 2 enable detailed documenta-
or time (in minutes)
or time (in minutes)
ific): Walking Impairment Questionnaire, others
ham Health Profile, EuroQol, Sickness Impact Profile, and others
L Questionnaire, PADQOL, and others
ll that apply:
sue
n type)
rtery; CT, computed tomography; CTA, computed tomographic angiography;
internal iliac artery; METS, metabolic equivalent of task score; MI, myocardial
, polytetrafluoroethylene; PVR, pulse volume recording; QoL/QOL, quality of
h Survey; TBI, toe-brachial index; TcPo2, transcutaneous partial pressure ofeters)
meters)
AD spec
, Notting
ascuQO
ABI
mplete a
lation tis
t:
n
unknow
n iliac a
nd; IIA,
se; PTFE
6 Healton of symptomatic status, vascular examination, and sever-
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story
History of present illness Indicate if the patient has been having any of the following symptoms and specify duration. Choose all that apply:
● No symptoms
● Abdominal pain
● Back pain
● Groin pain
● Leg pain
Past medical history Indicate if the patient has any of the following past medical history. Choose all that apply:
● Aneurysms or dissection
— Indicate location(s) and extent
● Prior aneurysm surgery
● Marfan syndrome
● Ehlers-Danlos syndrome
● Aortic surgery or endovascular repair
— Indicate location(s), type, and extent of repair
● Aortitis
● Other inflammatory or infectious disorders:
— Giant cell arteritis
— Takayasu’s arteritis
— Behçet’s syndrome
— Infection
Family history Indicate if the patient has any of the following family history. Choose all that apply:
● Aneurysms or dissections
— Indicate location(s)
● Marfan syndrome
● Ehlers-Danlos syndrome
● Loeys-Dietz syndrome
● Other
ysical Assessment
Abdominal Aorta
Body habitus Indicate the patient’s body habitus. Choose 1 of the following:
● Thin
● Normal
● Obese
Aortic pulsations Indicate the presence or absence of palpable abdominal aortic pulsations. Choose 1 of the following:
● Absent
● Present
Aortic pulsation characteristics Indicate the characteristics of aortic pulsation. Choose 1 of the following:
● Normal
● Expansile
Aortic diameter Estimate the diameter of AAA by palpation in inches or centimeters.
Abdominal bruit Indicate the absence or presence of abdominal bruit. Choose 1 of the following:
● Absent
● Present
Abdominal aortic area tenderness Indicate the absence or presence of tenderness in the abdominal aortic area. Choose 1 of the following:
● Absent
● Present
Abdominal tenderness Indicate the absence or presence of abdominal tenderness in areas other than the abdominal aortic area.
Choose 1 of the following:
● Absent
● Present
Abdominal tenderness location Indicate location of abdominal tenderness.
Lumbar spinal tenderness Indicate the absence or presence of lumbar spinal tenderness. Choose 1 of the following:
● Absent
● Present
Pulses Indicate the characteristics of pulses in the following locations:
● Femoral
● Popliteal
● Dorsalis pedis
● Posterior tibial
(Continued)
Ta
El
Di
318 Creager et al. JACC Vol. 59, No. 3, 2012
ACCF/AHA PAVD Data Standards January 17, 2012:294–357ble 3. Continued
ement Name Definition
Indicate if pulses are:
● 0: Absent
● 1: Diminished
● 2: Normal
● 3: Bounding or expansile
agnostic Procedures: Noninvasive
Ultrasonography
Date of procedure Indicate the date the procedure was performed (mo/d/y).
Aneurysm: type Indicate the type of aneurysm. Choose 1 of the following:
● Fusiform
● Saccular
● Pseudoaneurysm
Aneurysm: size Indicate the size of the aneurysm in millimeters in anteroposterior, transverse, and
longitudinal dimensions.
Aneurysm: distance Indicate the distance from the most proximal portion of the aneurysm to its most distal
portion in millimeters.
Thrombus Indicate if thrombus is present. Choose 1 of the following:
● Yes
● No
Dissection Indicate if dissection is present. Choose 1 of the following:
● Yes
● No
Leak Indicate if leak is present. Choose 1 of the following:
● Yes
● No
Magnetic Resonance Imaging
Date of procedure Indicate the date the procedure was performed (mo/d/y).
Method of MRA Indicate the method of MRA used. Choose 1 of the following:
● Contrast-enhanced MRA: White blood angiogram obtained by lowering the T1 relaxation
time of blood below the surrounding tissue
● Time-of-flight MRA: White blood angiogram generated by using the in-flow effect
Contrast used Indicate if gadolinium was used. Choose 1 of the following:
● Yes
● No
Aneurysm: location Indicate location of the aneurysm. Choose any of the following:
● Thoracoabdominal:
— Type 1
— Type 2
— Type 3
— Type 4
● Abdominal
— Indicate the proximal extent of the aneurysm:
Œ Suprarenal
Œ Juxtarenal
Œ Infrarenal
— Indicate whether the distal extent of the aneurysm is the aorta or whether it involves
the iliac arteries.
Œ Aorta
Œ Aortoiliac
– Bi-iliac
– Left iliac
– Right iliac
Aneurysm: type Indicate the type of aneurysm. Choose 1 of the following:
● Fusiform
● Saccular
● Pseudoaneurysm
Aneurysm: size Indicate the size of the aneurysm in millimeters by recording the maximum axial dimension
measured from outer margin to outer margin. The axial dimension should be perpendicular
to blood flow.
(Continued)
Ta
El
319JACC Vol. 59, No. 3, 2012 Creager et al.
January 17, 2012:294–357 ACCF/AHA PAVD Data Standardsble 3. Continued
ement Name Definition
Aneurysm: distance Indicate the distance from the most proximal portion of the aneurysm to the most distal
portion in millimeters.
Thrombus Indicate if thrombus is present. Choose 1 of the following:
● Yes
● No
Dissection Indicate if dissection is present. Choose 1 of the following:
● Yes
● No
Leak Indicate if leak is present. Choose 1 of the following:
● Yes
● No
Characteristics of other arteries Indicate other arteries imaged and indicate the patency or severity of stenosis.
Choose all that apply:
● Celiac artery
● Superior mesenteric artery
● Inferior mesenteric femoral artery
● Right renal artery
● Left renal artery
● Right/left CIA
● Right/left external iliac artery
● Right/left common femoral artery
Computed Tomography
CT method Indicate method of CT. Choose 1 of the following:
● Standard
● Spiral (helical)
● Electron beam
Date of procedure Indicate the date the procedure was performed (mo/d/y).
Contrast used Indicate the type of contrast used. Choose 1 of the following:
● Ionic
● Nonionic; specify:
— Monomer
— Dimer
Contrast volume Indicate the volume of contrast used in milliliters.
Slice thickness Indicate the slice thickness in millimeters.
Format: raw images Indicate if raw images were reviewed. Choose 1 of the following:
— Yes
— No
Format: reconstructed images Indicate if reconstructed images were reviewed. Choose 1 of the following:
● Yes. If yes, specify:
— Shaded surface images
— Maximum intensity projection
● No
Aneurysm: location Indicate location of the aneurysm. Choose any of the following:
● Thoracoabdominal:
— Type 1
— Type 2
— Type 3
— Type 4
● Abdominal
— Indicate the proximal extent of the aneurysm:
Œ Suprarenal
Œ Juxtarenal
Œ Infrarenal
— Indicate whether the distal extent of the aneurysm is the aorta or whether it involves
the iliac arteries:
Œ Aorta
Œ Aortoiliac
– Bi-iliac
– Left iliac
– Right iliac
(Continued)
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Aneurysm: type Indicate the type of aneurysm. Choose 1 of the following:
● Fusiform
● Saccular
● Pseudoaneurysm
Aneurysm: size Indicate the size of the aneurysm in millimeters by recording the maximum axial dimension
from outer margin to outer margin. The axial dimension should be perpendicular to blood flow.
Aneurysm: distance Indicate the distance from the most proximal portion of the aneurysm to the most distal
portion in millimeters.
Aortic neck morphology Indicate each of the following:
● Presence or absence of calcification
● Presence or absence of thrombus within the neck
● Degree of angulation in the neck
● Diameter of the neck
● Length of the neck from the lowest renal artery to the origin of the aneurysm
Thrombus Indicate if thrombus is present. Choose 1 of the following:
● Yes
● No
Dissection Indicate if dissection is present. Choose 1 of the following:
● Yes
● No
Leak Indicate if leak is present. Choose 1 of the following:
● Yes
● No
Characteristics of other arteries Indicate other arteries imaged and the patency or severity of stenosis. Choose all that apply:
● Celiac artery
● Superior mesenteric artery
● Inferior mesenteric femoral artery
● Right renal artery
● Left renal artery
● Right/left CIA
● Right/left external iliac artery
● Right/left common femoral artery
agnostic Procedures: Invasive
Catheter Angiography
Date of procedure Indicate the date the procedure was performed (mo/d/y).
Contrast Indicate the contrast used. Specify the following:
● Type
● Amount in milliliters
Fluoroscopy time Indicate the total fluoroscopy time recorded to the nearest 0.10 min. Time recorded should
include the total time for the procedure.
Aneurysm: location Indicate the location of the aneurysm. Choose any of the following:
● Thoracoabdominal:
— Type 1
— Type 2
— Type 3
— Type 4
● Abdominal
— Indicate the proximal extent of the aneurysm:
Œ Suprarenal
Œ Juxtarenal
Œ Infrarenal
— Indicate whether distal extent of aneurysm is the aorta or whether it involves the
iliac arteries:
Œ Aorta
Œ Aorto-iliac
– Bi-iliac
– Left iliac
– Right iliac
(Continued)
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Aneurysm: type Indicate type of aneurysm. Choose 1 of the following:
● Fusiform
● Saccular
● Pseudoaneurysm
Aneurysm: size Indicate the size of aneurysm in millimeters by recording the maximum axial dimension
measured from outer margin to outer margin. The axial dimension should be perpendicular
to blood flow.
Aneurysm: distance Indicate the distance from the most proximal portion of the aneurysm to the most distal
portion in millimeters.
Thrombus Indicate if thrombus is present. Choose 1 of the following:
● Yes
● No
Dissection Indicate if dissection is present. Choose 1 of the following:
● Yes
● No
Leak Indicate if leak is present. Choose 1 of the following:
● Yes
● No
Characteristics of other arteries Indicate other arteries imaged and the patency or severity of stenosis. Choose all that apply:
● Celiac artery
● Superior mesenteric artery
● Inferior mesenteric femoral artery
● Right renal artery
● Left renal artery
● Right/left CIA
● Right/left external iliac artery
● Right/left internal iliac artery
● Right/left common femoral artery
eatment:
vasive Therapeutic Procedures
Open AAA Repair
Date of procedure Indicate the date the procedure was performed (mo/d/y).
Operator name Last name, first, middle
Extent of aneurysm Indicate the extent of aneurysm in the following areas:
● Thoracoabdominal:
— Type 1
— Type 2
— Type 3
— Type 4
● Associated dissection
— Yes
— No
Infrarenal:
● Aorta
● Aortoiliac
— Bi-iliac
— Left iliac
— Right iliac
Clamping site: proximal Specify the proximal clamping site (or proximal control). This may include the following:
Thoracoabdominal:
● Above the mesenteric arteries
● Descending thoracic aorta
● Hypothermic circulatory arrest (no clamp)
● Distal to left subclavian artery
● Proximal to left subclavian artery
Infrarenal:
● Infrarenal
● Supraceliac
● Suprarenal
(Continued)
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Clamp time Indicate the following:
● Proximal time
● Time to restoration of visceral flow
● Total clamp time
Clamping site: distal Specify the distal clamping site. This may include the following:
Thoracic:
● Clamp site
● Segmental clamping
— Yes
— No
Infrarenal:
● Aorta
● CIA
● EIA and IIA
Neuroprotection technique
(thoracoabdominal)
Indicate neuroprotection techniques used. Choose all that apply:
● Clamp and sew (no protection)
● Preoperative imaging of spinal perfusion
● Retrograde perfusion
— Atrial-femoral bypass
— Axillo-femoral bypass
— Femoro-femoral bypass
— Shunt
— Others: specify
● Neurologic monitoring
● CSF drainage
● Systemic cooling
● Epidural cooling
● Reimplantation of intercostal arteries
— Specify how many
Graft Indicate type of graft used for procedure. Choose 1 of the following:
● Polyester woven
● Polyester knitted
● PTFE
Infrarenal:
● Tube graft
● Bifurcated graft
● Site of distal anastomoses (iliac or femoral arteries)
Management of visceral segment for
thoracoabdominal
Indicate how visceral segment was managed. Choose 1 of the following:
● Visceral patch, including celiac artery, SMA, right renal artery, and left renal artery.
● Visceral patch, including celiac artery, SMA, and right renal artery with left renal artery
either bypassed or implanted into aortic graft separately
● Individual bypasses to visceral and renal arteries.
● Indicate if visceral organ protection was used
— If so, specify type (perfusion, cold infusion)
Management of inferior mesenteric
artery
Indicate how inferior mesenteric artery was managed. Choose 1 of the following:
● Chronically occluded
● Oversewn
● Reimplanted
Intraoperative Details for
Open AAA Repair
Additional procedures Indicate other procedures performed. Choose all that apply:
● Renal artery bypass/endarterectomy
● Visceral artery procedure (specify)
● Other (specify)
Intraoperative complications Indicate if there were any intraoperative complications. Choose 1 of the following:
● Yes (specify)
● No
(Continued)
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Endovascular AAA Repair
Date of procedure Indicate the date the procedure was performed (mo/d/y).
Operator name Last name, first, middle
Aortic and iliac diameters and lengths Indicate aortic and iliac diameters and lengths
● Aortic diameter at lowest renal artery
● Aortic diameter 1.5 cm below lowest renal artery
● Aortic diameter at terminal aorta
● Maximum diameter of right CIA
● Maximum diameter of left CIA
● Minimum diameter of right EIA
● Minimum diameter of left EIA
● Length of aorta from lowest renal artery to aortic bifurcation
● Length from aortic bifurcation to right IIA
● Length from aortic bifurcation to left IIA
Graft Indicate type of graft used. Choose 1 of the following:
● Fixation
— Infrarenal
— Suprarenal
● Unibody
● Bifurcated
— 1 docking limb
— 2 docking limbs
Hypogastric arteries excluded Indicate number of hypogastric arteries excluded. Choose 1 of the following:
● 0
● 1
● 2
Management of inferior mesenteric
artery
Indicate how inferior mesenteric artery was managed. Choose 1 of the following:
● Chronically occluded/covered
● Coil occluded
Extension used Indicate extension used. Choose 1 of the following:
● Distal
— Number and size placed
— Landing zone
Œ CIA
Œ EIA
● Proximal
— Number and size placed
Adjunctive procedures Indicate the adjunctive procedures used. Choose 1 of the following:
● Adjunctive angioplasty or stent required. Specify the following:
— Side: indicate left or right
— Location: CIA, IIA, EIA
— Indication
● Conduit used for insertion of endograft. Specify the following:
— Side: indicate left or right
— Size and type of graft material of conduit
— Indication
● Accessory renal artery management. Specify the following:
— Side: indicate left or right
— Site of artery
— Size of artery
— Treatment:
Œ Embolization
Œ Coverage
● Iliac embolization. Specify the following:
— Side: indicate left or right
— Size: balloon or stent
— Indication
Endograft configuration Indicate the configuration of the endograft:
● Aorto–bi-iliac
● Aorto–uni-iliac graft with femoral artery to femoral artery bypass and
iliac artery occlusion
(Continued)
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Aortic neck morphology Indicate each of the following:
● Presence or absence of calcification
● Presence or absence of thrombus within neck
● Degree of angulation in the neck. Specify C-arm correction angle in degrees.
● Diameter of the neck
● Length of the neck from the lowest renal artery to the origin of the aneurysm
Intraoperative Details for Endovascular
AAA Repair
Endoleak present Indicate the type of endoleak present at the end of the case. Choose 1 of the following:
● Type I
● Type II
● Type III
● Type IV
● Undetermined
Limb kinking If present, specify the following:
● Site
● Size
● How it was resolved
Patency of arteries Indicate the patency of the arteries. Specify the following:
● Right/left renal arteries:
— Number
● Right/left accessory renal arteries
— Number
● Right/left common/external iliac arteries
Intraoperative complications Indicate if there were any intraoperative complications. Choose 1 of the following:
● Yes. If yes, choose all that apply:
— Arterial injury
Œ Indicate right or left side
Œ Indicate artery injured
— Embolization
Œ Indicate site
— Inadvertent covering of artery
Œ Indicate site
● No
Invasive Therapeutic Procedures: Other
Operative Details
Estimated blood loss Indicate the total amount of blood loss in milliliters.
Transfused blood products Indicate the blood products transfused to the patient. Choose all that apply:
● Auto transfused blood (specify volume)
● Packed RBCs
● Fresh frozen plasma
● Platelets
● Other (specify)
Operative time Indicate the total time of procedure in hours:minutes.
Invasive Therapeutic Procedures:
Postprocedure Details
Time to extubation Indicate when the patient was extubated post procedure. Choose 1 of the following:
● Immediate
● Postoperative day (specify day number)
Oral intake Indicate the day of oral intake.
Length of stay in ICU Indicate the length of stay in the ICU. Specify the number of days or indicate not
applicable.
Length of stay in step-down unit Indicate the length of stay in a step-down unit. Specify the number of days or indicate not
applicable.
Postoperative complications Indicate postoperative complications. Choose all that apply:
● Bleeding
● Cardiac
● Infections
● Pulmonary
(Continued)
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● Renal
● Neurological
● Reoperation
● Other (specify)
Total length of stay Indicate total length of stay in the hospital in number of days.
Discharge status (21) Indicate the patient’s discharge status. Choose 1 of the following:
● Discharged to home or self-care:
— This includes discharge to home; jail or law enforcement; home on oxygen if DME
only; any other DME only; group home, foster care, and other residential care
arrangements; outpatient programs such as partial hospitalization or outpatient
chemical dependency programs; assisted living facilities that are not state designated.
● Discharged/transferred to short-term general hospital for inpatient care
● Discharged/transferred to SNF with Medicare certification in anticipation of skilled care
● Discharged/transferred to ICF
● Discharged/transferred to standard rehabilitation facility
● Discharged/transferred to ventilator rehabilitation facility
● Discharged/transferred to another type of healthcare institution other than the above
● Patient died
tient Education/Counseling
Medication instruction Verbal and written medication instructions provided to patient and/or family
Recognition of new or
worsening symptoms
Verbal and written instructions provided to patient and/or family (by physician or nurse)
about new or worsening symptoms and when to call the physician
Diet counseling Advice given or discussion held with patient and/or family about the importance of diet in
relation to lowering cardiovascular risk. May include
● Sodium restriction
● Fluid restriction
● Referral to dietitian for weight management and/or advanced nutritional instruction
● Other (specify)
Smoking cessation counseling Advice given or discussion held with patient (by physician, nurse, or other personnel) about
the importance of stopping smoking. May include
● Counseling (may be basic or advanced)
● Written materials
● Referral to smoking cessation program
● Drugs to help with smoking cessation
Activity counseling Advice given or discussion held with patient and/or family about activity level and
restrictions in activity and/or exercise recommendations
llow-Up
Open repair Documentation of follow-up evaluation of patient 2 to 4 wk after discharge should include
● Physical examination
● Duplex ultrasound to check integrity of repair
CT scan of chest, abdomen, and pelvis should be considered within 5 y to evaluate for
synchronous aneurysms.
Endovascular/hybrid approach Documentation of follow-up evaluation of patient 4 wk after discharge should include
● Physical examination
● CT scan of abdomen and pelvis
● Plain film of abdomen to access stent integrity and migration
tcomes of Open AAA and Endovascular
pair
Time point Indicate the period at which outcome measures are assessed. Choose all that apply:
● Periprocedure (24 h)
● Procedure related (30 d)
● 3 mo
● 6 mo
● 1 y
● Other
Serious adverse event Indicate major clinical complications arising from management or treatment of the disease.
● Yes
— Specify serious adverse event from complication list below.
● No
(Continued)
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Complications of
endovascular repair
Indicate postoperative clinical events or conditions associated with endovascular procedure.
Choose all that apply:
● Major complication
— Death
— MI (also see cardiovascular complications below):
Œ Prolonged hospitalization
Œ Loss of limb or function of organ system
Œ Persistent or significant disability or incapacity
Œ Dissection
Œ Pseudoaneurysm
Œ Vessel thrombosis
Œ Vessel rupture
— Stroke
Œ Cerebral
Œ Spinal cord stroke
— Other life-threatening major complication (specify)
Œ Seroma
Œ Hematoma
Œ Mesenteric ischemia
Œ Renal failure
Œ Pneumonia
Œ Atheromatous embolization
Œ DVT
Œ Contrast nephropathy
Œ Contrast hypersensitivity
Œ Infection
Œ Requirement for intervention to prevent permanent impairment/damage
Œ Postimplant syndrome
● Minor complication (specify)
Complications of open repair Indicate complications of open surgery. Choose all that apply:
● Major complication
— Death
— MI (also see cardiovascular complications below):
Œ Prolonged hospitalization
Œ Loss of limb or function of organ system
Œ Persistent or significant disability or incapacity
Œ Dissection
Œ Pseudoaneurysm
Œ Vessel thrombosis
Œ Vessel rupture
— Stroke
Œ Cerebral
Œ Spinal cord stroke
— Other life-threatening major complication (specify)
Œ Seroma
Œ Hematoma
Œ Mesenteric ischemia
Œ Renal failure
Œ Pneumonia
Œ Atheromatous embolization
Œ DVT
Œ Contrast nephropathy
Œ Contrast hypersensitivity
Œ Infection
Œ Requirement for intervention to prevent permanent impairment/damage
Œ Postimplant syndrome
● Minor complication (specify)
inical Outcomes
Time point Indicate period at which outcome measures are assessed. Choose all that apply:
● 1 mo
● 3 mo
● 6 mo
● 1 y
(Continued)
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d pulse volume recordings. It also provides detailed elements
imaging tests, including duplex ultrasonography, magnetic
sonance angiography, computed tomographic angiography,
d catheter-based radiocontrast angiography, such as the artery
aged and the location and severity of stenoses. Data elements
levant to treatment include pharmacotherapy and exercise
habilitation for claudication. Table 2 also includes detailed
ta elements for both endovascular and open surgical revascu-
rization such as the target vessel, the specific procedure,
tcomes, and complications.
.3. AAA Table of Data Elements
able 3 provides a list and definition of data elements
levant to AAAs. Atherosclerosis is associated with the
generative changes found in the aortic wall of AAA,
ble 3. Continued
ement Name Definition
Graft or Endograft-Related Outcomes
Graft or endograft-related outcomes ● Patenc
— Prim
— Assi
— Seco
● Ischem
● Ischem
● Amput
Cardiovascular Outcomes
Cardiovascular outcomes New card
● Angina
● MI
● Corona
● CHF
● TIA
● Ischem
● Hemor
● Stroke
● Death
Outcomes Assessment
Noninvasive assessment
of outcome
● Pulse
● ABI
Long-Term Outcomes of Open AAA
Repair and Endovascular AAA Repair
Open AAA repair: long-term outcomes ● Infectio
● Aortoe
● Second
● Paragr
● Need f
Endovascular AAA repair: long-term
outcomes
● Infectio
● Aortoe
● Second
● Paragr
● Endole
● Need f
AAA indicates abdominal aortic aneurysm; ABI, ankle brachial index; CHF, cong
mography; DME, durable medical equipment; DVT, deep venous thrombosis;
ternal iliac artery; MI, myocardial infarction; MRA, magnetic resonance angiog
tery; SNF, skilled nursing facility; and TIA, transient ischemic attack.ough it is not necessarily causal. For this reason, it is arcluded in this document as a PAVD, although there are
her much less common causes of AAA, such as aortitis,
fection, aortic dissection, and inherited disorders of con-
ctive tissue. The data elements defined in Table 3 enable
cumentation of symptoms, relevant medical history, and
e physical assessment of AAA. The table comprises de-
iled elements of diagnostic imaging tests, including ultra-
nography, magnetic resonance imaging, and computed
mography, such as aneurysm type, size, location, and other
aracteristics. Additional elements relate to endovascular
d open surgical repair and include details of the procedures,
tcomes, and complications.
.4. Renal and Mesenteric Artery Disease
able of Data Elements
the context of this document, renal artery disease is defined
atherosclerotic disease that causes stenosis or occlusion of
pain
e loss
lar ischemic event
y revascularization
e
troke
n if ischemic or hemorrhagic)
tion
tulae
sm formation (remote from open AAA repair)
rysm formation (close or near old aneurysm repair)
dary procedure
tulae
urysm formation (remote from open AAA repair)
rysm formation (close or near old aneurysm repair)
dary procedure
eart failure; CIA, common iliac artery; CSF, cerebrospinal fluid; CT, computed
rnal iliac artery; ICF, intermediate care facility; ICU, intensive care unit; IIA,
TFE, polytetrafluoroethylene; RBC, red blood cell; SMA, superior mesentericy
ary
sted
ndary
ic rest
ic tissu
ation
iovascu
ry arter
ic strok
rhagic s
(unknow
examina
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story
Hypertension suggestive of renal artery
disease
● New-onset hypertension in those 30 or 55 y of age
● Accelerated hypertension
● Refractory hypertension
● Hypertension and concomitant atherosclerotic disease in other vascular territories
● Hypertension urgency/emergency
History of acute renal insufficiency History of reduced renal function for 3 mo (see “chronic kidney disease” element). Year of occurrence of
and precipitant for acute renal insufficiency (e.g., following treatment with angiotensin-converting enzyme
inhibitor or angiotensin receptor blocker) may be specified.
Chronic kidney disease Current or previous history of chronic kidney disease. Chronic kidney disease is defined as either kidney
damage or GFR  60 mL/min/1.73 m2 for 3 mo. Kidney damage is defined as pathologic abnormalities
or markers of damage, including abnormalities in blood or urine tests or imaging studies.
Indicate the patient’s stage of disease:
● Stage 0: No known kidney disease
● Stage 1: Kidney damage with normal or high GFR: 90 mL/min/1.73 m2
● Stage 2: Kidney damage with mildly decreased GFR: 60–89 mL/min/1.73 m2
● Stage 3: Moderately decreased GFR: 30–59 mL/min/1.73 m2
● Stage 4: Severely decreased GFR: 15–29 mL/min/1.73 m2
● Stage 5: Kidney failure: GFR 15 mL/min/1.73 m2 or on dialysis
Note: GFR may be estimated using the serum creatinine MDRD formula:
eGFR186 (serum creatinine)1.154 (age)0.203 (0.742 [if female]) (1.210 [if black])
Year of onset (first diagnosis) may be helpful.
Cause of chronic kidney disease (if present) ● Glomerular disease
● Tubular/interstitial disease
● Obstructive uropathy
● Polycystic kidney disease
● Other (specify)
● Unknown
Other kidney disorder ● Single kidney
● Cancer
● Nephrectomy
● Past trauma
● Other
Recurrent “flash” pulmonary edema without
coronary ischemia/left ventricular
dysfunction
Episodes of heart failure or pulmonary edema in the absence of a clear-cut cardiac cause such as
● Active coronary ischemia
● Systolic dysfunction on echocardiography
Other cardiovascular disease related to
renal artery disease
Coronary artery disease, PAD, carotid artery disease, AAA
ninvasive Diagnostic Procedures
Duplex Ultrasound
Date of procedure Indicate the date of the procedure (mo/d/y).
Artery imaged Indicate artery imaged:
● Right renal artery
● Left renal artery
Peak systolic velocity ● Aorta
● Proximal, mid-, distal right renal artery
● Proximal, mid-, distal left renal artery
Ratio of renal to aortic peak systolic
velocities
Record ratio for right and left renal arteries.
Specify for right and left renal arteries. Choose 1 of the following (31):
● 0%–59%
● 60%–99%
● Occluded
Location of stenosis Indicate side (right or left) and location of stenosis. Choose all that apply:
● Proximal
● Mid
● Distal
Kidney size Indicate maximum pole-to-pole renal length in centimeters.
(Continued)
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Resistive index (peak systolic velocityend diastolic velocity)/peak systolic velocity
● Specify for right and left kidney
Assessment of aorta Identify atherosclerosis, stenosis, occlusion, and/or aneurysm of the abdominal aorta.
Magnetic Resonance Angiography
Date of procedure Indicate the date of the procedure (mo/d/y).
Contrast use Indicate if gadolinium was used. Choose 1 of the following:
● Yes
● No
Location of stenosis Indicate side (right or left) and location of stenosis. Choose all that apply:
● Proximal
● Mid
● Distal
Location of stenosis: specific location in
renal artery
Indicate side (right or left) and location of stenosis. Choose all that apply:
● Main renal artery ostium
● Main renal artery postostium (1 cm from ostium)
● Segmental renal artery
● Intrarenal renal artery
Artery stenosis Indicate the severity of stenosis by quantitative analysis using the formula
100(1minimum lumen diameter)/maximum diameter of reference segment
Aorta Identify atherosclerosis, stenosis, occlusion, and/or aneurysm of the abdominal aorta.
Kidney size Indicate the maximum pole-to-pole renal length in centimeters.
Symmetry of renal perfusion Consistency and equality of renal blood flow in both kidneys
Symmetry of renal excretion Symmetry of rate of excretion of contrast agent from kidney
Renal artery morphology ● FMD
● Atherosclerosis
Computed Tomographic Angiography
Date of procedure Indicate the date of the procedure (mo/d/y).
Contrast used Indicate the type of contrast used. Choose 1 of the following:
● Ionic contrast
● Nonionic contrast; specify:
— Monomer
— Dimer
Contrast volume Indicate the volume of contrast used in milliliters.
Location of stenosis: specific location in
renal artery
Indicate the side (right or left) and location of stenosis. Choose all that apply:
● Main renal artery ostium
● Main renal artery postostium (1 cm from ostium)
● Segmental renal artery
● Intrarenal renal artery
Artery stenosis Indicate the severity of stenosis by quantitative analysis using the formula
100(1minimum lumen diameter)/maximum diameter of reference segment
Aorta Identify atherosclerosis, stenosis, occlusion, and/or aneurysm of the abdominal aorta.
Kidney size Indicate the maximum longitudinal renal length in centimeters.
Symmetry of renal perfusion Consistency and equality of renal blood flow in both kidneys
Symmetry of renal excretion Symmetry of rate of excretion of contrast agent from kidney
Renal artery morphology ● FMD
● Atherosclerosis
Captopril Renography
Date of procedure Indicate the date of the procedure (mo/d/y).
Operator Last name, first, middle
Symmetry Indicate whether there is equal uptake and excretion of radiotracer within kidneys.
Renogram curve Absolute time-activity curves pre- and postcaptopril, including peak and time to half-activity after peak
The time activity curve consists of the
● Vascular phase
● Secretory or functional phase
● Excretory phase
(Continued)
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vasive Diagnostic Procedure
Catheter-Based Angiography
Date of procedure Indicate the date of the procedure (mo/d/y).
Operator name Last name, first, middle
Vascular access site Specify the vascular access site.
Contrast agent Indicate the contrast agent used:
● Iodinated
— Ionic
— Nonionic
Œ Monomer
Œ Dimer
● Noniodinated (CO2)
Contrast volume Specify contrast volume given.
Fluoroscopy time Indicate the total fluoroscopy time recorded during the procedure to the nearest 0.10 min.
Catheter position ● Selective
● Nonselective
Renal perfusion Were all renal arteries identified (i.e., are there unexplained perfusion defects in the nephrogram phase)?
Location of stenosis: specific location in
renal artery
Indicate the side (right or left) and location of stenosis. Choose all that apply:
● Main renal artery ostium
● Main renal artery postostium (1 cm from ostium)
● Segmental renal artery
● Intrarenal renal artery
Artery stenosis Indicate the severity of stenosis by quantitative analysis using the formula
100(1minimum lumen diameter)/maximum diameter of reference segment
Aorta Identify atherosclerosis, stenosis, occlusion, and/or aneurysm of the abdominal aorta.
Kidney size Maximum longitudinal renal length in centimeters
Symmetry of renal perfusion Assess the consistency and equality of renal blood flow in both kidneys.
Renal artery morphology ● FMD
● Atherosclerosis
Complications Indicate complications related to the diagnostic procedure. If a concurrent endovascular procedure is
performed, report under endovascular complications. Choose all that apply:
● Pseudoaneurysm
● AV fistula
● Hematoma
● Dissection
● Vessel thrombosis
● Vessel perforation
● Atheromatous embolization
● Contrast nephropathy
● Contrast hypersensitivity
● Requirement of intervention to prevent permanent impairment/damage
● None
edical Therapies
Antihypertensive therapy Indicate name, dose, frequency of specific antihypertensive agent(s) used; address the use of
angiotensin-converting enzyme inhibitors/angiotensin II receptor antagonists.
Antilipidemic therapy Indicate the name, dose, and frequency of specific lipid-lowering agent(s) used.
Antiplatelet therapy Indicate the name, dose, and frequency of specific antiplatelet agent(s) used.
vasive Therapeutic Procedures
Renal Artery Angioplasty/Stenting
Date of procedure Indicate the date the procedure was performed (mo/d/y).
Operator Last name, first, middle
Angioplasty/stenting Choose 1 of the following:
● Balloon angioplasty alone
● Stent
Balloon length Indicate the length of the balloon used in millimeters.
Nominal balloon diameter Indicate the diameter of the balloon at initial inflation and final inflation in millimeters.
Target renal artery Indicate whether the target vessel for the procedure is the right or left renal artery.
(Continued)
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Current procedure part of clinical trial Indicate whether the procedure is part of a clinical trial. Choose one:
● Yes
If yes, indicate the trial type:
— IDE
— Postmarket approval
— Other (specify)
● No
Anesthesia Indicate if the patient received general anesthesia, conscious sedation, local anesthesia, or no anesthesia
during the current procedure.
Procedure Indications and
Anatomic Variables
Clinical indications ● Hypertension
● Renal insufficiency
● CHF/pulmonary edema
● Angina pectoris
Restenosis in target vessel after prior
renal stent
Note if the indication for the current procedure is restenosis in the target renal artery that was previously
treated with angioplasty and/or a stent.
● Renal artery restenosis is defined as 50% diameter stenosis at or adjacent to the site previously
treated with balloon angioplasty or a stent.
Contrast volume Indicate the volume of iodinated contrast injected during the procedure in milliliters.
Fluoroscopy time Indicate the total fluoroscopy time recorded during the procedure to the nearest 0.10 min. The time
recorded should include the total time for the procedure.
Contralateral renal artery occlusion Indicate if there is known 100% occlusion of the patient’s contralateral renal artery.
Spontaneous aortic or renal artery
dissection
Indicate if the patient has had a spontaneous renal artery dissection before the current procedure.
Procedure arterial access site Indicate the primary arterial access site used to perform the renal artery stenting procedure.
Note the location (right/left):
● Femoral
● Brachial
● Radial
● Axillary
Arterial access closure method ● List methods and devices in chronological order of closure.
● Indicate the method used to achieve hemostasis:
— Device
— Nondevice (such as manual compression)
Lesions
Target lesion location List the following:
● Ostial
● Proximal
● Mid
● Distal
● Intrarenal
Visible thrombus present Indicate if the target lesion contains thrombus as assessed by baseline angiography and implied by the
presence of filling defect.
Calcification Indicate if calcification is present. If present, specify the location.
Choose 1 of the following:
● None
● Mild
● Moderate
● Severe
Lesion length Indicate the length of the target lesion in millimeters as assessed by baseline angiography.
Minimal luminal diameter Indicate the MLD of the target lesion in millimeters as assessed by baseline angiography.
Minimal luminal diameter is defined as the minimum luminal diameter derived from the angiographic view
that shows the tightest point of the stenosis.
Diameter of distal renal artery Indicate the diameter of the nontapering distal segment of the renal artery measured at the intended
landing zone of the distal edge of the stent.
Preprocedure percent stenosis of
renal artery
Indicate the severity of stenosis by quantitative analysis using the formula
100(1minimum lumen diameter)/maximum diameter of reference segment
(Continued)
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Lesion treatment incomplete or aborted Indicate if the lesion treatment was incomplete or aborted. Choose 1 of the following:
● Yes
— If yes, note the reasons:
Œ Failure to gain vascular access
Œ Failure to engage ostium with guide catheter
Œ Unable to cross with guidewire
Œ Unable to deploy stent
Œ Failure to confirm significant stenosis
Œ Unable to cross balloon
Œ Cardiac ischemia
Œ Unable to deploy device
Œ Hypotension
Œ Hypertension
Œ Unable to deliver stent
Œ Other
● No
Embolic protection attempted Indicate if the operator tried to use an EPD. Choose 1 of the following:
● Yes
— If yes, indicate if predilatation before the balloon or stent was performed or not.
— If yes, list EPD in chronological order. Note if successfully deployed.
● No
Stent malposition Indicate if the stent was deployed in a location or position other than that for which it was intended.
Final MLD Indicate the final residual lumen diameter in millimeters.
Final percent stenosis of renal artery Indicate the percent stenosis post procedure by quantitative analysis using the formula
100(1minimum lumen diameter)/maximum diameter of reference segment
Device
Number of stents used (per artery) ● 1
● 1
Stent type Indicate the type of stent used. Choose all that apply:
● Balloon expandable
● Self-expanding
● Drug eluting
● Covered
Stent brand name Indicate the brand name of the stent used.
Stent model Indicate the model number of the stent used.
Stent manufacturer Indicate the manufacturer of the stent used.
Stent length Indicate the length of the stent used in millimeters.
Stent diameter Indicate the diameter of the stent used in millimeters.
Renal Artery Surgical Revascularization
Date of procedure Indicate the date of the procedure (mo/d/y).
Indications for the procedure Consider indications for renal artery revascularization. Choose all that apply:
● Clinical indications
— Hypertension
— Renal insufficiency
— CHF/pulmonary edema
— Angina pectoris
● Surgery-specific indications
— Repetitive failure of renal artery angioplasty/stent
— Need for aortic surgery (i.e., AAA repair)
Surgical procedures Indicate the surgical revascularization procedure:
● Renal artery endarterectomy
● Aortorenal bypass with either saphenous vein or synthetic material
● Extra-anatomic bypass: hepatorenal, splenorenal, ileorenal
tcomes of Endovascular/
en Surgical Procedures
Time points Indicate the period at which outcome measures are assessed. Choose all that apply:
● Periprocedure (24 h)
● Procedure related (30 d)
● 3 mo
(Continued)
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● 6 mo
● 1 y
Complications of endovascular procedure Indicate postoperative clinical events or conditions associated with the endovascular procedure.
Choose all that apply:
● Pseudoaneurysm
● AV fistula
● Hematoma
● Dissection
● Vessel thrombosis
● Vessel perforation
● Atheromatous embolization
● Contrast nephropathy
● Contrast hypersensitivity
● Requirement of intervention to prevent permanent impairment/damage
● Other (specify)
● None
Complications of open surgery Indicate complications of open surgery. Choose all that apply:
● Major complication
— Death
— MI (also see cardiovascular complications below):
Œ Prolonged hospitalization
Œ Loss of limb or function of organ system
Œ Persistent or significant disability or incapacity
Œ Vessel thrombosis
Œ Vessel rupture
— Stroke
Œ Cerebral
Œ Spinal cord stroke
— Other life-threatening major complication (specify)
Œ Seroma
Œ Hematoma
Œ Mesenteric ischemia
Œ Renal failure
Œ Pneumonia
Œ Atheromatous embolization
Œ DVT
Œ Graft thrombosis
Œ Atheromatous embolization
Œ Contrast nephropathy
Œ Contrast hypersensitivity
Œ Infection
Œ Requirement for intervention to prevent permanent impairment/damage
— Minor complication (specify)
Total length of stay Indicate the length of stay in the hospital in number of days.
Discharge status Indicate the patient’s discharge status. Choose 1 of the following:
● Discharged to home or self-care
— This includes discharge to home; jail or law enforcement; home on oxygen if DME only; any other
DME only; group home, foster care, and other residential care arrangements; outpatient programs
such as partial hospitalization or outpatient chemical dependency programs; assisted living facilities
that are not state designated.
● Discharged/transferred to short-term general hospital for inpatient care
● Discharged/transferred to SNF with Medicare certification in anticipation of skilled care
● Discharged/transferred to ICF
● Discharged/transferred to standard rehabilitation facility
● Discharged/transferred to ventilator rehabilitation facility
● Discharged/transferred to another type of healthcare institution other than the above
● Patient died
tient Education/Counseling
Medication instruction Verbal and written medication instructions provided to patient and/or family
Recognition of new or worsening symptoms Verbal and written instructions provided to patient and/or family (by physician or nurse) regarding new or
worsening symptoms and when to call the physician
(Continued)
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Diet counseling Advice given or discussio
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● Other (specify)
Smoking cessation counseling Advice given or discussio
of stopping smoking. Ma
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● Categories of blood pr
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story
Risk Factors
Atherosclerosis Known atherosclerosis in any vascular territory
Patient Assessment: Symptoms
Indicate if any of the symptoms
listed below are present
Symptoms suggestive of
mesenteric ischemia
● Abdominal fullness, bloating, discomfort after eating that ultimately results in “fear of food”
● Weight loss, anorexia, failure to thrive
● All associated with presence of atherosclerosis in other vascular beds or the presence of cardiac dysrhythmia
(i.e., atrial fibrillation) or severe left ventricular dysfunction
Postprandial abdominal pain Pain, bloating, early satiety following ingestion of food and/or liquids
Fear of eating Avoidance of eating because of predictable abdominal pain, often resulting in more frequent eating of small
amounts of food
Weight loss Specify amount of weight loss in pounds or kilograms.
Malnutrition The patient manifests malnutrition because of inadequate caloric intake to meet metabolic demands, as well as
dehydration.
Malabsorption/steatorrhea ● Diarrhea
● Oily stool
● Floating stool
ysical Examination
Complete Abdominal Examination
Body habitus Describe the patient’s body habitus. Choose one of the following:
● Thin
● Normal
● Obese
Aortic diameter Estimate abdominal aortic diameter by palpation in inches or centimeters.
Abdominal bruit Indicate the absence or presence of abdominal bruit. Choose 1 of the following:
● Absent
● Present
Rectal Exam
Digital rectal examination Examine the lower rectum to check for abnormalities in the rectum and stool (hemoccult).
Stool testing for occult blood Occult blood present or absent?
boratory Testing
Amylase, lipase Indicate the following:
● Date of test
● Value
● Unit of measurement
● Normal range
Stool fat content ● Microscopic: Indicate the number of stainable lipid globules per high-powered microscope field.
● Gravimetric: Indicate the collection period (number of days), reference range, and test result in grams of lipid
per 24 h.
● Titrimetric
Fecal occult blood Occult blood present or absent?
ninvasive Diagnostic Procedures
Mesenteric Artery Duplex Ultrasound
Date of procedure Indicate the date of the procedure (mo/d/y).
Operator Last name, first, middle
Peak systolic velocity measurements ● Aorta
● Celiac artery
● Superior mesenteric artery
● Inferior mesenteric artery
Ratio of mesenteric artery to aorta
peak systolic velocities
Record ratio for celiac, superior mesenteric, and inferior mesenteric arteries.
Location of stenosis Indicate the location of the stenosis. Choose all that apply:
● Celiac artery
● Superior mesenteric artery
● Inferior mesenteric artery
(Continued)
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Category of stenosis Specify for celiac, superior mesenteric, and inferior mesenteric arteries. Choose 1 of the following:
● 0–69%
● 70%–99%
● Occlusion
Computed Tomographic Angiography
Date of procedure Indicate the date the procedure was performed (mo/d/y).
Contrast used Indicate the type of contrast used. Choose 1 of the following:
● Ionic contrast
● Nonionic contrast; specify:
— Monomer
— Dimer
Contrast volume Indicate volume of contrast used in milliliters.
Artery imaged Indicate artery imaged. Choose all that apply:
● Celiac artery
● Superior mesenteric artery
● Inferior mesenteric artery
Location of stenosis Indicate the location of the stenosis.
Artery stenosis Indicate the severity of stenosis by quantitative analysis using the formula
100(1minimum lumen diameter)/maximum diameter of reference segment
Aneurysm Dilation of a mesenteric artery to a diameter 1.5 times the nondilated diameter
Small and large bowel Indicate if there is thickening of the small or large bowel wall. Choose 1 of the following:
● Yes
● No
Free air in the abdomen Indicate the presence of free air in the abdomen. Choose 1 of the following:
● Yes
● No
Mesenteric venous thrombosis Patent venous opacification of the superior mesenteric vein and portal vein
Pneumatosis coli Indicate the presence of pneumatosis coli:
● Yes
● No
Magnetic Resonance Angiography
Date of procedure Indicate the date the procedure was performed (mo/d/y).
Contrast use Indicate if gadolinium was used. Choose 1 of the following:
● Yes
● No
Artery imaged Indicate the artery imaged. Choose all that apply:
● Celiac artery
● Superior mesenteric artery
● Inferior mesenteric artery
Location of stenosis Indicate the location of the stenosis.
Artery stenosis Indicate the severity of stenosis by quantitative analysis using the formula
100(1minimum lumen diameter)/maximum diameter of reference segment
Aorta Identify atherosclerosis, stenosis, occlusion, and/or aneurysm of the abdominal aorta.
Small and large bowel Indicate if there is thickening of the small or large bowel wall. Choose 1 of the following:
● Yes
● No
Free air in the abdomen Indicate the presence of free air in the abdomen. Choose 1 of the following:
● Yes
● No
Mesenteric venous thrombosis Patent venous opacification of the superior mesenteric vein and portal vein
Pneumatosis coli Indicate the presence of pneumatosis coli:
● Yes
● No
agnostic Procedure: Invasive
Catheter-Based Angiography
Date of procedure Indicate the date the procedure was performed (mo/d/y).
Operator Last name, first, middle
(Continued)
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Artery imaged Indicate the artery imaged. Choose all that apply:
● Celiac artery
● Superior mesenteric artery
● Inferior mesenteric artery
Artery stenosis Indicate the severity of stenosis by quantitative analysis using the formula
100(1minimum lumen diameter)/maximum diameter of reference segment
Aorta Identify atherosclerosis, stenosis, occlusion, and/or aneurysm of the abdominal aorta.
Diffuse vasospasm Indicate the presence or absence of vasospasm consistent with nonocclusive mesenteric ischemia.
Mesenteric venous thrombosis Indicate whether the superior mesenteric vein and portal vein are patent or occluded by thrombus.
vasive Therapeutic Procedures:
theter Based
Mesenteric Artery Angioplasty Stenting
Date of procedure Indicate the date the procedure was performed (mo/d/y).
Operator Last name, first, middle
Angioplasty/stenting Choose one:
● Balloon angioplasty alone
● Stent
Balloon length Indicate the length of balloon used in millimeters.
Nominal balloon diameter Indicate the diameter of the balloon at initial inflation and final inflation in millimeters.
How many stents used (per artery)? ● 1
● 1
Stent type Indicate type of stent used. Choose all that apply:
● Balloon expandable
● Self-expanding
● Drug eluting
● Covered
Stent brand name Identify the brand name of the stent used.
Stent model Identify the model number of the stent used.
Stent manufacturer Identify the manufacturer of the stent used.
Stent length Indicate the length of the stent used in millimeters.
Stent diameter Indicate the diameter of the stent used in millimeters.
Target mesenteric artery Indicate whether the target vessel for the procedure is the celiac, superior mesenteric, and/or
inferior mesenteric artery.
Current procedure part of clinical trial Indicate whether the procedure is part of a clinical trial. Choose 1 of the following:
● Yes
— If yes, indicate the trial type:
Œ IDE
Œ Postmarket approval
Œ Other (specify)
● No
Anesthesia Indicate if the patient received general anesthesia, conscious sedation, local anesthesia, or no anesthesia during
the current procedure.
Procedure Indications and
Anatomic Variables
Clinical indication ● Symptoms of mesenteric ischemia
● Weight loss
● Malnutrition
● Other
Restenosis in target vessel after prior
mesenteric artery stent
Note if the indication for the current procedure is restenosis in the target mesenteric artery that was previously
treated with angioplasty and/or a stent.
Contrast volume Indicate the volume of iodinated contrast injected during the procedure in milliliters.
Fluoroscopy time Indicate the total fluoroscopy time recorded during the procedure to the nearest 0.10 min. The time recorded
should include the total time for the procedure.
(Continued)
Ta
El
In
Su
338 Creager et al. JACC Vol. 59, No. 3, 2012
ACCF/AHA PAVD Data Standards January 17, 2012:294–357ble 5. Continued
ement Name Definition
Procedure arterial access site Indicate the primary arterial access site used to perform the mesenteric artery stenting procedure.
Note the location (right/left):
● Femoral
● Brachial
● Radial
● Axillary
Arterial access closure method ● List methods and devices in chronological order of closure.
● Indicate the method used to achieve hemostasis:
— Device
— Nondevice (such as manual compression)
Lesions
Target lesion location Indicate the location of the target lesion.
Visible thrombus present Indicate if the target lesion contains thrombus as assessed by baseline angiography and implied by the presence
of filling defect.
Calcification Indicate if calcification is present. If present, specify the location. Choose 1of the following:
● None
● Mild
● Moderate
● Severe
Lesion length Indicate the length of the target lesion in millimeters as assessed by baseline angiography.
Minimal luminal diameter Indicate the MLD of the target lesion in millimeters as assessed by baseline angiography.
Diameter of distal mesenteric artery Indicate the diameter of the nontapering distal segment of the mesenteric artery measurement at the intended
landing zone of the distal edge of the stent.
Preprocedure percent stenosis of
mesenteric artery
Indicate the severity of stenosis by quantitative analysis using the formula
100(1minimum lumen diameter)/maximum diameter of reference segment
Lesion treatment incomplete or
aborted
Indicate if the lesion treatment was incomplete or aborted. Choose 1 of the following:
● Yes
— If yes, note reasons:
Œ Failure to gain vascular access.
Œ Failure to engage ostium with guide catheter
Œ Unable to cross with guidewire
Œ Unable to deploy stent
Œ Failure to confirm significant stenosis
Œ Unable to cross balloon
Œ Cardiac ischemia
Œ Unable to deploy device
Œ Hypotension
Œ Hypertension
Œ Unable to deliver stent
Œ Other
● No
Embolic protection attempted Indicate if the operator tried to use an EPD:
● Yes
— If yes, indicate if predilatation before balloon or stent was performed or not.
— If yes, list EPD in chronological order. Note if successfully deployed.
● No
Stent malposition Indicate if the stent was deployed in a location or position other than that for which it was intended.
Final minimal luminal diameter Indicate the final residual lumen diameter in millimeters.
Final percent stenosis of
mesenteric artery
Indicate the severity of stenosis by quantitative analysis using the formula
100(1minimum lumen diameter)/maximum diameter of reference segment
How many stents used (per artery)? ● 1
● 1
vasive Therapeutic Procedure:
rgical Revascularization
Aortomesenteric Bypass Graft Surgery
Date of procedure Indicate the date the procedure was performed (mo/d/y).
Proximal anastomosis Indicate the location of proximal anastomosis with graft (i.e., supraceliac aorta, iliac artery).
(Continued)
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Distal anastomosis Indicate the location of distal anastomosis with graft (i.e., mid-celiac artery, mid-SMA).
Conduit Indicate the type of graft material used for bypass (e.g., synthetic, autologous).
Mesenteric Endarterectomy
Date of procedure Indicate the date the procedure was performed (mo/d/y).
Outcomes of Endovascular/
Open Surgery Procedures
Time points Indicate the period at which outcome measures are assessed. Choose all that apply:
● Periprocedure (24 h)
● Procedure related (30 d)
● 3 mo
● 6 mo
● 1 y
Complications of endovascular
procedure
Indicate postoperative clinical events or conditions associated with an endovascular procedure.
Choose all that apply:
● Pseudoaneurysm
● AV fistula
● Hematoma
● Dissection
● Vessel thrombosis
● Vessel perforation
● Atheromatous embolization
● Contrast nephropathy
● Contrast hypersensitivity
● Infection
● Requirement of intervention to prevent permanent impairment/damage
Complications of open surgery Indicate complications of open surgery. Choose all that apply:
● Major complication:
— Death
— MI (also see cardiovascular complications below)
— Stroke (ischemic, hemorrhagic, unknown type)
● Other life-threatening major complication (specify):
— Prolonged hospitalization
— Persistent or significant disability or incapacity
— Vessel thrombosis
— Vessel rupture
— Seroma
— Hematoma
— Renal failure
— Bowel infarction
— Other end-organ damage
— Pneumonia
— DVT
— Graft thrombosis
— Atheromatous embolization
— Requirement of intervention to prevent permanent impairment/damage
— Infection
● Minor complication (specify)
Total length of stay Indicate the length of stay in the hospital in number of days.
Discharge status Indicate the patient’s discharge status. Choose 1 of the following:
● Discharged to home or self-care
— This includes discharge to home; jail or law enforcement; home on oxygen if DME only; any other DME
only; group home, foster care, and other residential care arrangements; outpatient programs such as partial
hospitalization or outpatient chemical dependency programs; assisted living facilities that are not state
designated.
● Discharged/transferred to short-term general hospital for inpatient care
● Discharged/transferred to an SNF with Medicare certification in anticipation of skilled care
● Discharged/transferred to an ICF
● Discharged/transferred to standard rehabilitation facility
● Discharged/transferred to ventilator rehabilitation facility
● Discharged/transferred to another type of healthcare institution other than the above
● Patient died
(Continued)
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ble 5. Continued
ement Name Definition
Patient Education/Counseling
Medication instruction Verbal and written medication
Recognition of new or worsening
symptoms
Verbal and written instructions
worsening symptoms and whe
Diet counseling Advice given or discussion held
cardiovascular risk. May includ
● Sodium restriction
● Fluid restriction
● Referral to dietitian for weig
● Other (specify)
Smoking cessation counseling Advice given or discussion held
stopping smoking. May include
● Counseling (may be basic or
● Written materials
● Referral to smoking cessatio
● Drugs to help with smoking
Activity counseling Advice given or discussion held
exercise recommendations
Follow-Up
Open repair Documentation of evaluation of
● Physical examination
● Imaging (e.g., ultrasound, M
Endovascular Documentation of evaluation of
● Physical examination
● Imaging (e.g., ultrasound, M
inical Outcomes
Time points Indicate the period at which ou
● 1 mo
● 3 mo
● 6 mo
● 1 y
Patient assessment Assess recurrent signs and sym
● Appetite
● Caloric intake
● Nutritional status
● Presence or absence of pos
● Food avoidance/tolerance
● Weight loss/gain
Adverse events ● Recurrent bowel ischemia/in
● Repeat revascularization
● Bowel resection
● MI
● Stroke (ischemic, hemorrhag
● Other adverse event
● Death
AV indicates atrioventricular; CT, computed tomography; DME, durable medi
termediate care facility; IDE, investigational device exemption; MI, myocardial
esenteric artery; and SNF, skilled nursing facility.larization therapy. ar.5. Extracranial Carotid and Vertebral Artery
isease Table of Data Elements
the context of this document, extracranial carotid artery
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tient History
Asymptomatic Indicate if the patient is asymptomatic. No prior stroke or TIA
Symptomatic Indicate the onset and duration of symptoms.
Previous stroke Previous stroke is defined as an acute loss of neurological function caused by an ischemic or hemorrhagic
event with residual symptoms for at least 24 h or symptoms for 24 h with evidence of acute infarction (e.g.,
by CT or MRI).
If present, record stroke type:
● Ischemic
● Intracerebral hemorrhage
● Subarachnoid hemorrhage
● Unknown
If ischemic, list the most likely etiologies:
● Large-artery atherosclerosis of the extracranial vessels (e.g., carotid)
● Large-artery atherosclerosis of the intracranial vessels (e.g., middle cerebral artery stenosis)
● Cardioembolism
● Small-vessel occlusion (lacunar)
● Ischemic stroke of other determined etiology (e.g., arterial dissection)
● Ischemic stroke of undetermined etiology
Transient ischemic attack (TIA) Documented history of TIA consisting of a transient episode of neurological dysfunction caused by focal brain,
spinal cord, or retinal ischemia, without acute infarction
Note the following:
● Right retinal
● Right hemispheric
● Left retinal
● Left hemispheric
● Vertebrobasilar
● Unknown distribution
Date of first and most recent episode
ASA grade Choose 1 of the following:
● Grade I: Normal, healthy
● Grade II: Mild systemic disease that does not limit activity
● Grade III: Severe systemic disease that limits activity but is not incapacitating
● Grade IV: Incapacitating systemic disease that is constantly life threatening
● Grade V: Moribund; not expected to survive 24 h with or without surgery
History of dementia History of dementia, Alzheimer’s disease, chronic confusion (at least 1 mo in duration), or senility
Year of onset (first diagnosis) may be helpful.
Seizures Indicate if the patient has a documented history of epilepsy.
Hemorrhage Indicate if the patient has a hemorrhage. Choose all that apply:
● Intraparenchymal
● Intraventricular
● Subarachnoid
● Subdural
Cause of carotid/vertebral stenosis Select any of the following that apply
● Atherosclerosis
● FMD
● Dissection
● Vasculitis (Takayasu’s or giant cell arteritis)
● Irradiation
● Restenosis following CEA
● Restenosis following CAS
● Restenosis following vertebral angioplasty/stenting
atomic High-Risk Conditions
Previous neck radiation Indicate if the patient had previous radiation therapy to the neck before the current admission or procedure.
Previous neck surgery
(other than CEA)
Indicate if the patient had a previous extensive (i.e., radical) neck dissection (other than CEA) before the
current admission or procedure.
Previous carotid intervention Yes or no. If yes, within 30 d, 31–180 d, or 180 d?
Note:
● Right CEA
● Right CAS
● Left CEA
● Left CAS
(Continued)
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Previous vertebral intervention Yes or no. If yes, within 30 d, 31–180 d, or 180 d?
Note:
● Left
● Right
● Proximal
● Distal
Previous ipsilateral CEA Yes or no
Tracheostomy present Indicate if the patient has an open tracheostomy at the time of the current procedure.
Cranial nerve palsy (32,33) Indicate if patient has a history of cranial nerve palsy/palsies. Choose 1 of the following:
● Yes
— If yes, indicate all nerves involved:
Œ Recurrent laryngeal or its parent nerve, the vagus nerve
Œ Hypoglossal
Œ Facial
Œ Other
● No
morbid Cardiopulmonary
nditions
History of chronic lung disease History of chronic lung disease (e.g., chronic obstructive pulmonary disease, chronic bronchitis, emphysema, restrictive
lung disease) or currently receiving long-term treatment with inhaled or oral pharmacological therapy (e.g.,
beta-adrenergic agonist, anti-inflammatory agent, leukotriene receptor antagonist, or steroid)
Year of onset (first diagnosis) may be helpful.
On home oxygen Indicate if, before the current procedure, the patient has been receiving home oxygen therapy for treatment of chronic
lung disease.
NYHA class III or IV in last 6 wk Indicate if the patient’s highest NYHA cardiac functional class has been class III or IV at any time within 6 wk before the
current procedure. Patients in NYHA classes III and IV have anginal or heart failure symptoms at rest and/or resulting in
marked limitation of physical activity. NYHA classes III and IV are formally defined as follows:
● Class III: Patient has cardiac disease resulting in marked limitation of physical activity. Patient is comfortable at rest.
However, less than ordinary physical activity (e.g., walking 1 to 2 level blocks or climbing 1 flight of stairs) causes
fatigue, palpitations, dyspnea, or anginal pain.
● Class IV: Patient has dyspnea at rest that increases with any physical activity. Patient has cardiac disease resulting in
inability to perform any physical activity without discomfort. Symptoms may be present even at rest. If any physical
activity is undertaken, discomfort is increased.
Note: For patients without cardiac disease or patients with NYHA class I or II, code No.
tient Assessment
Carotid bruits Indicate if carotid bruits are present. Choose 1 of the following:
● Yes
— Left
— Right
— Bilateral
● No
● Not assessed
Supraclavicular bruits Indicate if supraclavicular bruits are present. Choose 1 of the following:
● Yes
— Left
— Right
— Bilateral
● No
● Not assessed
NIH Stroke Scale score Indicate if the NIHSS was used. Choose 1 of the following:
● Yes
— Indicate scores done before the procedure, immediately after the procedure, before discharge, and other.
● No
(Continued)
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Modified Rankin Stroke Scale
score
Indicate the patient’s score:
Score Description
0 No symptoms at all
1 No significant disability despite symptoms; able to carry out all usual duties and activities
2 Slight disability; unable to carry out all previous activities but able to look after own affairs without assistance
3 Moderate disability; requiring some help but able to walk without assistance
4 Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs
without assistance
5 Severe disability; bedridden, incontinent, and requiring constant nursing care and attention
6 Death
Barthel Index Indicate if the Barthel Index was measured. Choose 1 of the following:
● Yes
— Indicate scores done before the procedure, immediately after the procedure, before discharge, and other.
● No
Specific neurologic findings Indicate the presence or absence of the following:
● Hemiparesis
● Upper motor neuron facial weakness
● Lower motor neuron facial weakness
● Dysphasia
● Hemisensory loss
● Visuospatial neglect
● Branch retinal artery occlusion
● Central retinal artery occlusion
● Dysarthria
● Gait ataxia
● Disconjugate gaze
● Tongue deviation
● Nystagmus
agnostic Procedures
Carotid Duplex Ultrasound
Date of procedure Indicate the date of the procedure (mo/d/y).
Location of measurement Measure each of the following in the right CCA, right ICA, left CCA, and left ICA.
Plaque characteristics Indicate if any of the following are present:
● No plaque
● Homogeneous plaque (stable)
● Heterogeneous plaque (unstable)
● Surface irregularity
Intima-media thickness Indicate intima-media thickness in millimeters.
CCA systolic velocity Measure systolic velocity in proximal, mid, and distal segments of CCA.
Measure velocity in centimeters per second.
CCA diastolic velocity Measure diastolic velocity in proximal, mid, and distal segments of CCA.
Measure velocity in centimeters per second.
ICA systolic velocity Measure systolic velocity in proximal, mid, and distal segments of ICA.
Measure velocity in centimeters per second.
ICA diastolic velocity Measure diastolic velocity in proximal, mid, and distal segments of ICA.
Measure velocity in centimeters per second.
Peak ICA: distal CCA systolic
velocity ratio
Indicate systolic velocity radio measured in centimeters per second. Choose 1 of the following:
● 2.0
● 2.0–4.0
● 4.0
Degree of stenosis Indicate range of stenosis:
● Normal
● 1%–49%
● 50%–69%
● 70%–99%
● Complete occlusion
(Continued)
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Carotid stent stenosis Indicate the range of stenosis after carotid stenting:
● Normal
● 1%–49%
● 50%–69%
● 70%–99%
● Complete occlusion
Carotid bifurcation location Indicate the location of carotid bifurcation. Choose 1 of the following:
● Normal
● High
Vertebral artery flow direction Indicate the direction of artery flow for the right and left vertebral artery. Choose 1 of the following:
● Forward
● Reversed
● No flow detected
CT Angiography
Date of procedure Indicate the date the procedure was performed (mo/d/y).
Radiologist Last name, first, middle
Location of measurement Measure each of the following in the right CCA, right ICA, left CCA, and left ICA.
Luminal diameter of CCA Measure diameter in millimeters.
Luminal diameter of ICA Measure diameter in millimeters.
Degree of stenosis Use the NASCET method for measurement of stenosis defined by the formula
% stenosis100(1minimum luminal diameter at the lesion site)/diameter of nontapering segment of distal ICA
Nonobstructed diameter of ICA Measure diameter in millimeters.
Plaque characteristics Indicate if any of the following are present:
● Calcifications
● Ulceration
● Tandem lesion
Intracranial atherosclerotic
disease
Indicate if intracranial atherosclerotic disease (50% stenosis) is present in the distribution in either the right or left
ICAs: Yes or no.
Other vascular abnormality Indicate if another vascular abnormality is present, including aneurysm, AVM, etc.
Magnetic Resonance Angiography
Date of procedure Indicate the date of the procedure (mo/d/y).
Location of measurement Measure each of the following in the right CCA, right ICA, left CCA, and left ICA.
Diameter of CCA Measure diameter in millimeters.
Diameter of ICA Measure diameter in millimeters.
Degree of stenosis Use the NASCET method for measurement of stenosis defined by the formula
% stenosis100(1minimum luminal diameter at the lesion site)/diameter of nontapering segment of distal ICA
Nonobstructed diameter of ICA Measure diameter in millimeters.
Plaque Indicate if any of the following are present and describe:
● Fibrous cap thickness in millimeters
● Fibrous cap disruption
● Intraplaque lipid content
● Intraplaque hemorrhage
Tandem lesion Indicate yes or no.
Other vascular abnormality Indicate if another vascular abnormality is present, including aneurysm, AVM, etc.
Intracranial atherosclerotic
disease
Indicate if intracranial atherosclerotic disease (50% stenosis) is present in the distribution of either the right or left ICA:
Yes or no.
vasive Therapeutic Procedures:
rotid and Vertebral Artery Stenting
Date of procedure Indicate the date the procedure was performed (mo/d/y).
Target carotid vessel Indicate whether the target vessel is the right or left carotid artery for the current procedure: Right or left.
Target vertebral artery Indicate whether the target vessel is the right or left vertebral artery for the current procedure: Right or left.
Is the current procedure part of a
clinical trial?
Yes or no. If yes, note trial type:
● Postmarket surveillance
● Premarket approval
● IDE
● Other (specify)
(Continued)
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Anesthesia Indicate if the patient received general anesthesia, local anesthesia, or no anesthesia during the current procedure. If
1 method was used, code it General.
Procedure Indications and
Anatomic Variables
Target lesion symptomatic
within past 6 mo
Indicate if the patient has had neurologic symptoms related to the target lesion in the past 6 mo.
Restenosis in target vessel
after prior CAS
Note if the indication for the current procedure is restenosis in the target carotid artery that was previously treated with
angioplasty and/or a stent. Carotid artery restenosis is defined as 50% diameter stenosis at or adjacent to the site
previously treated with balloon angioplasty or a stent.
Restenosis of target vessel
after prior CEA
Note if the indication for the current procedure is restenosis in the target carotid artery that was previously treated with
carotid artery endarterectomy. Restenosis is defined as renarrowing within or adjacent to a prior endarterectomy site,
evidenced by 50% diameter stenosis.
Carotid lesion difficult to access
surgically
Indicate if the lesion is difficult to access surgically for CEA.
Yes or no
Note: Lesions that are difficult to access include those that are high in the neck (e.g., at or above the level of C2) and
those that are within the proximal one half or one third of the CCA, at or below the clavicle, rendering endarterectomy
either difficult or impossible.
Vertebral lesion difficult to
access surgically
Indicate if the lesion is difficult to access surgically.
Yes or no
Aortic arch type Indicate the patient’s aortic arch type configuration. The 3 types of aortic arch are based on the relationship of the
innominate artery to the aortic arch. The more inferior the origin of the target artery (i.e., type II or III aortic arch), the
greater the difficulty in gaining access to the carotid artery.
Category:
● Type I
● Type II
● Type III
Contrast volume Indicate the volume of iodinated contrast injected during the procedure in milliliters.
Fluoroscopy time Indicate the total fluoroscopy time recorded during the procedure to the nearest 0.10 min. The time recorded should
include the total time for the procedure.
Contralateral carotid occlusion Indicate if there is known 100% occlusion of the patient’s contralateral carotid artery.
Contralateral vertebral occlusion Indicate if there is known 100% occlusion of the patient’s contralateral vertebral artery.
Bovine arch Indicate if the patient’s aortic arch is bovine, in which the right brachiocephalic and left carotid arteries share a common
trunk from the aortic arch.
Procedure arterial access site Indicate the primary arterial access site used to perform the CAS procedure.
Note the location:
● Femoral
● Direct carotid puncture
● Direct vertebral puncture
● Brachial
● Radial
● Axillary exposure
● Carotid cut down
● Vertebral cut down
Arterial access closure method List methods and devices in chronological order of closure. Indicate the method used to achieve hemostasis. Methods
should include devices and nondevices such as manual compression.
Tandem lesions Indicate if there is evidence of tandem lesions. Choose 1 of the following:
● Yes
— Specify location(s)
● No
Intracranial stenosis Indicate if there is evidence of intracranial lesions. Choose 1 of the following:
● Yes
— Specify location(s)
● No
Other intracranial pathology Indicate if there is evidence of other intracranial pathology. Choose 1 of the following:
● Yes
— Specify type
● No
(Continued)
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Lesions and Devices
Target lesion location List the following:
● Isolated CCA
● Isolated ICA
● Bifurcation
● Vertebral ostia
● Vertebral artery ostia
● Midcervical vertebral
Visible thrombus present Indicate if the target lesion contains thrombus as assessed by baseline angiography and implied by the presence of
filling defect.
Ulceration Indicate if the target lesion is ulcerated as assessed by baseline angiography.
Calcification Indicate if calcification is present. If present, specify the location.
Choose 1 of the following:
● None
● Mild
● Moderate
● Severe
Lesion length Indicate the length of the target lesion in millimeters as assessed by baseline angiography.
Minimal luminal diameter Indicate the MLD of the target lesion in millimeters as assessed by baseline angiography. The MLD is defined as the
minimum luminal diameter derived from the angiographic view that shows the tightest point of the stenosis.
Diameter of distal ICA Indicate the diameter of the nontapering distal segment of the ICA for NASCET measurement at the intended landing
zone of the distal edge of the stent (where the vessel is no longer tapered and the walls become parallel).
Note: NASCET was a randomized clinical trial that compared the safety and efficacy of CEA to medical therapy for the
prevention of stroke in symptomatic patients.
Preprocedure percent stenosis
of the carotid artery
Indicate the percent stenosis preprocedure, which is calculated as follows:
1. When the tightest stenosis is in the ICA or at the carotid bifurcation, use the NASCET method. Percent diameter
stenosis is calculated as 1(minimum luminal diameter at the lesion site/diameter of nontapering segment of the
distal ICA). The nontapering site is where the walls of the ICA become parallel.
2. Do not use the NASCET method if the distal lumen collapses from a low-flow situation. In such cases, enter 99%
because the stenosis may be graded as a near-occlusion.
3. For stenosis localized to the CCA, percent diameter stenosis is calculated as 1(minimum luminal diameter/diameter
of the adjacent normal segment of the CCA).
Preprocedure percent stenosis
of the vertebral artery
Indicate preprocedure percent stenosis calculated as follows:
When the tightest stenosis is in the cervical vertebral artery (origin to dural entry), percent diameter stenosis is
calculated as 1(minimum luminal diameter of the nontapering segment of the distal vertebral artery). The nontapering
site is where the walls of the vertebral artery become parallel.
Lesion treatment incomplete or
aborted
Indicate if the lesion treatment was incomplete or aborted: Yes or no. If yes, note the reason(s):
● Failure to gain vascular access
● Unable to cross with guidewire
● Unable to cross with balloon
● Unable to deploy stent
● Arrhythmia
● Failure to confirm significant stenosis
● Difficult to access because of tortuosity
● Cardiac ischemia
● Hypotension
● Hypertension
● Unable to deliver stent
● Acute neurological event
● Other
Embolic protection attempted Indicate if the operator tried to use an EPD:
● Yes
— Indicate if predilatation was done before balloon or stent.
— List EPD devices in chronological order.
— Note if successfully deployed.
● No
If yes, indicate if predilatation was done before balloon or stent.
● Yes
● No
If yes, list EPD devices in chronological order.
(Continued)
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Predilatation Indicate if predilatation was performed before the attempted stent implantation or after EPD: Yes or no
Stents implanted Were stents implanted? Yes or no. If yes, list stents in chronological order with the following information:
● Stent
● Brand
● Model
● Manufacturer
Stents tapered Yes or no
Stent(s) diameter Indicate the diameter of the stent. If a tapered stent was used, indicate the smallest diameter of the tapered stent in
millimeters.
Stent(s) length Indicate the length of the stent in millimeters.
Stent(s) malposition Indicate if the stent was deployed in a location or position other than that for which it was intended.
Postdilatation performed Was postdilatation performed? Yes or no. If yes, note the following:
● Nominal balloon diameter in millimeters
● Maximum inflation pressure in atmospheres
Final MLD Indicate the final residual lumen diameter in millimeters.
Final percent stenosis for
carotid artery
Indicate percent stenosis postprocedure, calculated as follows:
1. For an ICA site, use NASCET methodology. Percent diameter stenosis is calculated as 1(minimum residual luminal
diameter within the treated site/diameter of the nontapering segment of the distal ICA). The nontapering site is where
the walls of the ICA become parallel.
2. For a lesion and interventional site localized to the CCA, percent diameter stenosis is calculated as 1(minimum
residual luminal diameter/diameter of the adjacent normal segment of the CCA).
Final percent stenosis for
vertebral artery
Value is dependent on the largest stenosis using essentially similar NASCET criteria for vertebral disease.
vasive Therapeutic Procedures:
rotid Endarterectomy
Date of procedure Indicate the date the procedure was performed (mo/d/y).
Operator Last name, first, middle
Is the current procedure part of a
carotid trial?
Yes or no. If yes, note the type of trial:
● Postmarket surveillance
● Premarket approval
● IDE
● Other (specify)
Target carotid vessel Indicate whether the target vessel is the right or left carotid artery for the current procedure:
● Right
● Left
● Common
● Bifurcation
● Distal internal
Anesthesia Indicate if the patient received general anesthesia, local anesthesia, or no anesthesia during the current procedure. If
1 method of anesthesia was given, code it General.
Endarterectomy technique Standard or eversion
Procedure Indications and
Anatomic Variables
Target lesion symptomatic
within past 6 mo
Indicate if the patient has had neurologic symptoms related to the target lesion in the past 6 mo.
Target lesion symptomatic
within past 3 mo
Yes or no
Target lesion symptomatic
within past 6 wk
Yes or no
Restenosis in target vessel
after prior CEA
Note if the indication for the current procedure is restenosis in the target carotid artery that was previously treated with
CEA. Restenosis is defined as renarrowing within or adjacent to a prior endarterectomy site, evidenced by 50%
diameter stenosis.
Contralateral carotid artery
occlusion
Indicate if there is known 100% occlusion of the patient’s contralateral carotid artery.
Contralateral carotid artery
stenosis
Yes or no
(Continued)
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Spontaneous carotid artery
dissection
Indicate if the patient has had a spontaneous carotid artery dissection before the current procedure: Yes or no.
If yes, note the location:
● Common carotid
● Carotid bifurcation
● Distal internal
Tandem lesions Yes or no. If yes, note the location.
Intracranial stenosis Yes or no. If yes, note the location.
Other intracranial pathology Yes or no. If yes, note the type.
Intraprocedural Information
Patch utilization Standard technique?
● Yes
— If yes, indicate the type of patch (e.g., Dacron, PTFE, bovine pericardium, vein).
● No
Thrombus present on
direct visual inspection
Indicate if a thrombus (blood clot) was present on direct visual inspection intraoperatively during the CEA procedure.
Monitoring technique used Note the following:
● Awake monitoring
● Selective monitoring based on EEG, stump pressure, SSEP, motor-evoked potential, anatomic, or other factor
(describe).
Shunting used Indicate if a shunt was used. If yes, note the following:
● Selective shunt based on EEG, stump pressure, SSEP, motor-evoked potential, anatomic, or other factor (describe)
● Was a shunt indicated but not technically possible?
Surgical procedure terminated Indicate if the CEA procedure was terminated: Yes or no. If yes, note the reason(s):
● Hypotension
● Hypertension
● Nerve compromise
● Excessive scar tissue
● Carotid artery thrombosis
● Difficulty with anesthesia
● Difficulty with suction
● ICA string sign or atresia
● Cardiac instability
● Inability to implement shunting
● Excessive bleeding
● Inability to access lesion because of anatomical lesions
● Other (specify)
Intraoperative completion
evaluation
Check all that apply:
● None
● Standard Doppler
● Arteriogram (include findings)
● Duplex scan (include findings)
Intraoperative complications Indicate any of the following:
● Reopening of carotid artery (note indication and findings)
● Technical difficulties (describe)
Patient outcome ● Normal neurologic exam
● Deficit (describe)
Medications
Antiplatelet therapy, aspirin Yes or no. If yes, note type.
Contraindicated clopidogrel Yes or no
Contraindicated ticlopidine Yes or no
Contraindicated other Yes or no
Intraoperative anticoagulation Indicate the drug and dose used
ocedural Outcomes
Intraprocedural/intraoperative
adverse events
Indicate adverse event(s) that occurred during or after the procedure. Specify time of occurrence relative to procedure:
● Abrupt closure
● Spasm requiring treatment
● Loss of external carotid
● Distal intracranial embolization
● Embolization (systemic)
(Continued)
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● Embolization (carotid)
● Thrombosis
● Occlusive untreated dissection
● Arrhythmia requiring treatment
● Hypotension requiring treatment
● Hypertension requiring treatment
● Stroke (ischemic, hemorrhagic, unknown type)
● TIA
● Amaurosis fugax
● Seizure
● Puncture site complications
● Death (or death in lab)
● Intubation or resuscitation
● Stent malposition
● Embolic protection retrieval
● Intracranial hemorrhage
● Other (specify)
Results ● Procedure technical failure—unable to deploy stent
● Procedure terminated for stenosis 70%
● Procedure terminated because of complication before deployment
● Procedure technical success without complications
● Procedure technical success with complications
Acute occlusion Indicate if there is acute occlusion 24 h after the procedure.
Residual stenosis Note:
● Right
● Left
● Bilateral
Right-side percent stenosis Indicate right-side percent stenosis.
Left-side percent stenosis Indicate left-side percent stenosis.
Stent migration/deformation Stent located in planned landing zone with complete lesion coverage
Distal embolization Occlusion of cerebral arteries or periprocedural neurologic deficit resulting from dislodgment of atheromatous debris or
thrombus from the procedural site
Postprocedural complications in
hospital
Indicate if any of the following occurred:
● None
● Arrhythmia requiring treatment
● Hypotension requiring treatment
● Hypertension requiring treatment
● MI
● New unstable angina
● Electrocardiographic changes
● Cardiac enzyme elevations
● Pulmonary embolism
● Stroke (ischemic, hemorrhagic, unknown type)
● Deterioration in Modified Rankin Scale score
● TIA
● Amaurosis fugax
● Seizure
● Intracranial hemorrhage
● Hyperperfusion syndrome
● Other neurologic complication (specify)
● Secondary carotid intervention (specify)
● Vessel thrombosis or ischemia of extremity
● Puncture site complications
● Pseudoaneurysm
● Pseudoaneurysm vascular repair
● Hematoma (local or retroperitoneal) (indicate if transfusion required)
● Other bleeding (indicate if transfusion required)
● Access site infection
● Creatinine increase 1.0 mg/dL
● Hemodialysis
(Continued)
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● Pneumonia
● Urinary tract infection
● Sepsis
● Death
● Other (specify)
tient Education/Counseling
Medication instruction Verbal and written medication instructions provided to patient and/or family
Recognition of new or
worsening symptoms
Verbal and written instructions provided to patient and/or family (by physician or nurse) regarding new or worsening
symptoms and when to call the physician
Diet counseling Advice given or discussion held with the patient and/or family about diet counseling related to lowering
cardiovascular risk. May include
● Sodium restriction
● Fluid restriction
● Other (specify)
Referral to dietician for diet
counseling
Referral to dietitian for weight management and/or advanced nutritional instruction
Activity counseling Advice given or discussion held with the patient and/or family about activity level and restrictions in activity and/or
exercise recommendations.
Smoking cessation counseling Advice given or discussion held with the patient (by physician, nurse, or other personnel) about the importance of
stopping smoking. May include
● Counseling (may be basic or advanced)
● Written materials
● Referral to smoking cessation program
● Drugs to assist for smoking cessation
Plan for follow-up care Documentation of plan for follow-up care with physician and/or nurse
Should include date of follow-up
Patient referral Patient referred to other care such as neurology, neurosurgery, vascular surgery, cardiology clinic/office.
Transitional care (specify duration):
● Home health care
● Nurse case manager
● Hospice or palliative care
● Home telemonitoring
● Ambulatory cardiac telemetric monitoring (e.g., mobile cardiac outpatient telemetry)
● Period of time enrolled in the program and/or qualitative characterization of the level of the
patient’s success/participation in the program(s) may be specified.
Discharge status Indicate the following:
● Discharge NIHSS score
● Discharge Modified Rankin Scale score
● Discharge Barthel Index
● Cranial nerve injury
● Technical defects requiring revision
● Stroke (ischemic, hemorrhagic, unknown type)—note date
● TIA (single or multiple)—note date
● Amaurosis fugax
● MI (Q wave or non–Q wave)—note date
tcomes
Time points Indicate the period at which outcome measures are assessed. Choose all that apply:
● 1 mo
● 3 mo
● 6 mo
● 1 y
Follow-up visit Documentation of follow-up evaluation for patients with established carotid/vertebral arterial disease should include
● Patient history
● Functional status
● Physical examination
● Laboratory or other tests
Date of visit Indicate the date of visit (mo/d/y).
Follow-up NIHSS (See scale above.)
(Continued)
Ta
El
351JACC Vol. 59, No. 3, 2012 Creager et al.
January 17, 2012:294–357 ACCF/AHA PAVD Data Standardsble 6. Continued
ement Name Definition
Repeat duplex ultrasound
performed
Indicate if repeat duplex ultrasound was performed in any of the following time frames:
● Before discharge
— Yes
— No
● 3 mo
— Yes
— No
● 6 mo
— Yes
— No
● Annually
— Yes
— No
Right-side percent stenosis Indicate right-side percent stenosis.
Left-side percent stenosis Indicate left-side percent stenosis.
MRA or CTA performed Indicate if MRA or CTA was performed in any of the following time frames:
● Before discharge
— Yes
— No
● 3 mo
— Yes
— No
● 6 mo
— Yes
— No
● Annually
— Yes
— No
Right-side percent stenosis Indicate right-side percent stenosis.
Left-side percent stenosis Indicate left-side percent stenosis.
Follow-up Modified Rankin Scale
score
(See scale above.)
Follow-up Barthel Index (See scale above.)
Stroke Indicate stroke type:
● Ischemic
● Hemorrhagic
● Unknown
Indicate whether or not the patient was hospitalized.
Reason for termination Indicate the reason for termination.
Death Note the following:
● Date
● Cause
● Date of the last visit in which the patient was evaluated
● Death within 30 d of last visit
● Death 30 d after last visit
Repeat Hospitalization
Date of admission Indicate the date of admission (mo/d/y).
Primary reason for readmission Stroke, TIA, MI, other
Repeat duplex ultrasound
performed?
Yes or no
Right-side percent stenosis Indicate right-side percent stenosis.
Left-side percent stenosis Indicate left-side percent stenosis.
Was repeated MRA, CTA, or
conventional angiogram
performed?
Yes or no
Target lesion revascularization Indicate whether CAS was performed.
Target vessel revascularization Indicate whether CEA or CAS was performed.
(Continued)
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